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ABSTRACT 
ELIZABETH L. YANIK: Cancer following Combination Antiretroviral Therapy Initiation: 
Incidence Patterns and Effects of Antiretroviral Response   
(Under the direction of Dr. Sonia Napravnik) 
 
Among HIV-infected patients, cancer is a leading cause of morbidity and mortality. 
While combination antiretroviral therapy (ART) has reduced the incidence of Kaposi 
sarcoma (KS) and non-Hodgkin lymphomas, the burden of non-AIDS-defining cancers 
(NADCs) is increasing.  However, the patterns and predictors of cancer incidence following 
ART initiation remain poorly characterized.   
The Centers for AIDS Research Network of Integrated Clinical Systems, a 
collaboration of 8 United States HIV clinical cohorts, was used to evaluate the incidence and 
timing of cancer among patients initiating first ART, defined as ≥3 antiretrovirals, between 
1996 and 2011.  Poisson regression was used to estimate incidence rates. Cox regression 
was used to estimate adjusted hazard ratios to identify patient characteristics at ART 
initiation associated with subsequent cancer incidence. 
Associations between immunologic ART response and NADC incidence were also 
evaluated among patients with ≥1 CD4 count and HIV RNA measurement by six months 
after ART initiation. Six month CD4, latest CD4, and CD4 count-years, a cumulative 
measure of CD4 lymphopenia, were used as measures of immunologic ART response and 
were considered with 0, 6, and 12-month exposure lags. Inverse probability weights were 
applied to Cox regression to account for time-varying confounding from the coincident 
virologic ART response. 
Incidence for KS and lymphoma (Hodgkin, non-Hodgkin) were highest in the first six 
months post-ART start and plateaued thereafter, while incidence for all other cancers 
combined increased with time from ART initiation.  A lower CD4 count at ART initiation was 
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associated with greater incidence of KS, lymphomas, and human papillomavirus-related 
cancers. Calendar year of ART initiation was not associated with cancer incidence.  All 
measures of immunologic response were associated with virus-related NADC incidence 
independent of CD4 count at ART initiation, but none were associated with virus-unrelated 
NADC incidence.  These associations persisted when measures were assessed with 6 and 
12-month exposure lags. 
Our results underscore recommendations for earlier HIV diagnosis followed by 
prompt ART initiation. They also highlight the need for cancer prevention and screening 
efforts throughout the course of HIV care, particularly among patients with poor immunologic 
response to ART. 
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I. SPECIFIC AIMS 
 
 Recent years have seen rising incidence rates of non-AIDS-defining cancers 
(NADCs) among the HIV population.  However, the etiologic pathways through which HIV 
increases cancer risk and the effects of HIV-specific exposures, such as antiretroviral 
therapy, on cancer incidence and cancer outcomes are still poorly understood.  While it 
would be intuitive that combination antiretroviral therapy (ART) use would reduce the risk of 
NADCs through immune reconstitution, studies have shown mixed associations with ART 
use and NADC incidence, and incidence of some NADCs has increased in the ART era 
compared to the pre-ART era[1-4]. While these studies have provided a descriptive 
characterization of NADC incidence in the era of ART, most may not clearly characterize the 
causal association of modern antiretroviral treatment with malignancies because of latencies 
between the relevant exposure window and cancer diagnosis, and differences in competing 
risks between patients from different treatment eras.  To better understand the relationship 
between ART use and cancer incidence the following aims are proposed.  
 
Aim 1:  Describe the incidence and timing of cancer diagnoses following combination 
antiretroviral treatment (ART) initiation. 
            Hypothesis 1.1: Incidence will be higher within the first year following ART initiation 
for cancers that may increase due to immune recovery (e.g., Hodgkin’s lymphoma) and for 
cancers detectable through screening tests due to increased medical care.   
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            Hypothesis 1.2:  After an initial decrease in incidence following the first year after 
ART initiation, incidence will increase with time after ART initiation due to chronologic aging 
and cumulative and/or incident carcinogen exposure, including alcohol and tobacco use. 
            Hypothesis 1.3:  The overall incidence of virus-related cancers will be on average 
greater than the incidence of non-virus-related cancers. 
 
Aim 2:  Examine the association of immunologic ART response with the incidence of non-
AIDS-defining cancers (NADCs) accounting for time-fixed and time-varying confounders. 
Hypothesis 2.1: After controlling for confounders, NADC incidence rates will be 
lower in patients who achieve immune reconstitution as measured by six month CD4 count, 
latest CD4 and CD4 count loss-years, a cumulative measure of immunologic response. 
Hypothesis 2.2:  Immune reconstitution following ART initiation will be more strongly 
associated with reduced NADC incidence rates when an exposure lag is introduced 
compared to when immune reconstitution is assessed proximal to NADC diagnosis. 
 
The Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems 
(CNICS), an observational clinical cohort collaboration, will be used for these analyses.  
CNICS has extensive information on antiretroviral treatment, cancer incidence and staging, 
other diagnoses, and laboratory measurements from eight HIV clinics in the United States.  
Overall, CNICS includes over 25,000 HIV-infected patients with over 400 incident cancers 
cases after ART initiation and over 150 incident cases of NADCs occurring in patients six 
months after ART initiation.   
 
  
  
II. BACKGROUND AND SIGNIFICANCE 
 
A.  Cancer in the HIV population 
 
 From early in the HIV epidemic, cancer has been a prominent source of illness in the 
HIV population.  Initially, this was mostly due to cancers categorized as AIDS-defining 
(ADCs) which served as markers of advanced HIV progression, specifically Kaposi sarcoma, 
non-Hodgkin lymphoma, and invasive cervical cancer.  With the advent of combination 
antiretroviral treatment (ART) in 1996, HIV patients are now living longer and facing a new 
array of non-AIDS-defining illnesses.  As incidence and mortality rates from ADCs have 
declined, non-AIDS-defining cancers (NADCs) now make up a substantial proportion of the 
cancer burden in HIV populations and have become one of the leading causes of death 
among HIV-infected individuals in developed countries[1, 5-8].  HIV-infected individuals 
diagnosed with cancer often present with more advanced disease and have a poorer 
prognosis than the general population[4, 9-13].  Several studies have demonstrated that 
HIV-infected individuals are at increased risk of many NADCs when compared to HIV-
uninfected individuals, particularly those with known infectious causes[8, 14-16].  In fact, in 
more recent years relative risks of NADCs such as anal cancer and Hodgkin lymphoma 
have been shown to be similar to their AIDS-defining counterparts (cervical cancer and non-
Hodgkin lymphoma, respectively)[17, 18].  This indicates a need for primary prevention to 
reduce ADC and NADC incidence as well as identification of groups that may benefit from 
more frequent screening and faster identification of symptoms.  In addition, a better 
understanding of the etiologic causes for the high incidence in HIV populations may better 
inform future interventions both in the HIV-infected and general populations.  
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 A number of the most common NADCs in the HIV population have much higher 
incidence rates than the HIV-uninfected population. While HIV-infected individuals have 
about 2-3 times the risk of developing any NADC compared to HIV-uninfected individuals, 
they have 28 times the risk of developing anal cancer, 11 times the risk of developing 
Hodgkin lymphoma, 3 times the risk of developing lung cancer, 6 times the risk of 
developing liver cancer, and 4 times the risk of developing skin cancer[15, 19].  The virus-
related NADCs have particularly high incidence rates in the HIV population, with the two 
most common virus-related NADCs being anal cancer (related to human papillomavirus 
infection) and Hodgkin lymphoma (related to Epstein-Barr virus infection)[14].  While 
survival rates for both ADCs and NADCs have increased in the ART era, cancer has 
become a larger contributor to death as infectious causes of death have decreased more 
dramatically[7, 20-22].  In a recent study of mortality conducted within the Centers for AIDS 
Research Network of Integrated Clinical Systems, virus-related NADC cases had a 2-year 
survival rate of 72% while virus-unrelated NADCs had a 2-year survival rate of 51% and 
ADCs had a 2-year survival rate of 59%[23]. While survival rates among diagnosed 
NADCs have improved in the ART era, the incidence of NADCs has increased, adding to 
the burden of disease[24].  The overall rise in incidence of NADCs since the introduction of 
ART appears to be almost entirely attributable to increased rates of virus-related 
NADCs[25]. 
 While behavioral differences between the HIV population and the general 
population are major contributors to the high risk of cancer in HIV-infected individuals 
these differences do not appear to fully account for the increased risk.  For instance in the 
Multicenter AIDS Cohort Study of gay and bisexual men, anal cancer risk appeared 
increased in HIV-infected men compared to HIV-uninfected men even after accounting for 
sexual behaviors[26].  A study of liver cancer found that HIV infection did not predict liver 
cancer risks independently from the effects of hepatitis C infection and alcohol abuse[27].  
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However, HIV-infected liver cancer cases have been reported to have a history of alcohol 
abuse less frequently than their HIV-uninfected cases, and HIV infection may impact 
cancer risk indirectly through a loss of control of chronic hepatitis infection[24, 28].  Several 
studies of lung cancer have found that HIV-infected individuals have increased risk 
compared to HIV-uninfected individuals independent of the effects of smoking behaviors, 
most notably in patients with low CD4 counts[17, 29-31].  These findings suggest that 
beyond a higher frequency of risk behaviors that increase NADC incidence in HIV 
populations, HIV disease may have direct effects on cancer risk.   
 
B.  Hypothesized Effects of HIV on Cancer Risk 
 
 While a number of biologic mechanisms may account for the higher risk of cancer 
in the HIV population, immunosuppression clearly may play a role in increasing the risk of 
infections, the persistence of infections, or the loss of control of latent infections related to 
oncogenic processes[24, 32-34].  The relationship of immunosuppression with cancer has 
been clearly established for the two most common ADCs, Kaposi sarcoma and Non-
Hodgkin lymphoma, in which the cancers have been linked with human herpes-8 virus and 
Epstein-Barr virus respectively.  Incidence of these two malignancies is closely associated 
with immunosuppression, and incidence decreases with ART use[1, 3, 35-37].  
Immunosuppression may also explain the preponderance of infection-related cancers in 
the HIV population[14, 38, 39].  This mechanism is further supported by evidence that the 
majority of cancers with increased incidence in the HIV population have also been found to 
have increased incidence in populations of transplant recipients, another group of 
immunosuppressed individuals[40, 41].   
 While cervical cancer and NADCs have been less strongly linked to 
immunosuppression, associations persist.  Both cervical and anal cancer incidence are 
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inversely associated with CD4 count and nadir CD4 count[2, 18, 26, 37, 42, 43].  This is 
further supported by evidence that HIV-related immunosuppression is associated with 
increased persistence of HPV, increased replication of oncogenic HPV types, and higher 
incidence of cervical cytological abnormalities[43-46].  Hodgkin lymphoma has shown an 
inverse association with CD4 count in some populations[47, 48] and a “U”-shaped 
association in others, in which the highest incidence is seen in those with CD4 counts 
between 200-250 cells/mm3 [24, 49].  This could possibly be due to an increase in risk of 
Hodgkin’s lymphoma as a part of immune reconstitution inflammatory syndrome (IRIS) in 
which diseases may worsen or be ‘unmasked’ during the immune reconstitution process 
following ART initiation[24, 50].  IRIS has previously been implicated in cases of Kaposi 
sarcoma and Non-Hodgkin lymphoma[51].  Liver cancer has also been associated with low 
CD4 counts, while associations have thus far been inconsistent for lung cancer[3, 29, 32, 
52].  Other virus-unrelated cancers have not shown conclusive associations with immune 
status, though there has been indication of a decreased risk of colorectal cancer with 
higher CD4 count[3, 17, 53].   
 In addition to the effects of immunodeficiency, persistent viral replication in patients 
with HIV may increase inflammation in turn increasing the risk of NADCs through increases 
in cellular replication and resulting DNA damage[34, 54].  This mechanism may be of 
particular importance for virus-unrelated cancers with increased risk in HIV populations.  
Uncontrollable viremia has been shown to predict risk of Kaposi sarcoma and Non-
Hodgkin lymphoma independent of CD4 count[17, 32, 36, 55].  While one study has found 
an association of anal cancer with increased duration of high viremia, this result has not 
been replicated in other studies[17, 26, 32]. Clear associations with viral replication have 
not been demonstrated for other NADCs[17, 29, 32].  This may partially be due to limited 
power to assess cancer-specific effects in most studies with small numbers of cancer 
cases, particularly if the effects of viral replication are small.  For AIDS-related lymphomas, 
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cumulative viral replication predicts incidence better than latest HIV viral load, but 
associations of cumulative measures of viremia with other types of cancer have not been 
assessed[55]. 
 If immunosuppression or viral replication is causally associated with higher cancer 
incidence we would expect the successful use of antiretroviral therapy in HIV patients to 
reduce cancer risk, including incidence of ADCs and NADCs, as well as, viral and non-viral 
mediated cancers. 
 
C.  Antiretroviral Use and Cancer 
 
 The incidence of Kaposi sarcoma and non-Hodgkin lymphoma have clearly 
declined since the introduction of ART in 1996, and individual risk for these cancers is 
greatly reduced with the initiation of ART[32, 56-58].  Despite the intuitive hypothesis that 
antiretroviral therapy would also decrease the risk of NADCs associated with HIV infection, 
studies of this association have been inconclusive.  Several descriptive studies have 
compared NADC incidence between the pre-ART era and the combination ART era 
(generally using 1996 as the beginning of the combination ART era in the United States).   
The majority of these studies have found either no change or an increase in NADC 
incidence in the combination ART era, particularly anal cancer and Hodgkin lymphoma[2, 
3, 18, 26, 49, 56, 59-61].  Much of this increase is due to the aging of the HIV population, 
however increases appear to persist after adjustment for age[2, 49, 56, 59, 60].  While 
these ecologic studies are helpful for descriptive purposes, we should be hesitant to draw 
any conclusions about causation without individual treatment data or information on other 
individual level factors.  In addition, these studies may not appropriately account for the 
significant differences in competing risks between the two eras.  Specifically, prior to the 
introduction of effective antiretroviral treatment most HIV-infected patients were dying of 
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aggressive infectious causes and seldom lived long enough to develop diseases with 
longer latency periods such as NADCs. 
 A number of studies have also assessed the association of current ART use or ever 
vs. never ART use with incidence of NADCs.  Most of these studies have also found either 
no association[3, 26, 29, 32] or positive associations[2, 62] between exposure to ART and 
NADCs.  A study of the association of ART use with liver cancer hinted at a protective 
association, but estimates of the association were imprecise due to a limited number of 
cancer outcomes[52].  These studies highlight the importance of screening measures even 
after successful treatment with ART; however, because oncogenic processes start long 
before diagnosis, examining ART use at the time of diagnosis may be missing the relevant 
window of exposure.  For virus-related NADCs in particular, the effect of ART may be most 
prominent at the time of oncogenic viral infection, which likely occurs long before cancer 
diagnosis.  Those infected with oncogenic viruses during an untreated HIV-infected time 
period likely may not develop diagnosable disease until after entry into care and initiation 
of ART.  NADCs also may be more likely to be diagnosed after ART initiation because of 
more patient engagement in clinical care after the start of treatment. Finally, categorizing 
ART use as ‘ever vs. never’ or ‘current vs. not current’ may also oversimplify a treatment 
exposure that may differ dramatically by patient in terms of duration, adherence, and 
efficacy.    
 
D. Cancer after Antiretroviral Initiation 
  
 Regardless of the absence or presence of a causal association between 
antiretroviral use and cancer risk, the majority of cancer diagnoses in the HIV populations 
in developed countries now occur in individuals after the initiation of ART[2, 32, 50].  A few 
studies have described trends in the incidence of specific cancers after ART initiation.  
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Hodgkin lymphoma was observed to occur at the highest rates within the first three months 
after ART initiation in a French HIV cohort, with rates similar to those seen in antiretroviral 
naïve patients after six months[50].  Another study assessed the association of duration of 
ART exposure with anal cancer incidence, but only 19 cases were included, and while the 
association appeared to be slightly protective it was not statistically significant[42].  The 
trends in cancer incidence after ART initiation have not been described for most specific 
cancer types, and no study has compared incidence trends in this time period between 
different cancer types.  Cancer incidence after ART initiation would be expected to vary 
over time given the many changes that occur in patients over time after ART initiation 
including viral suppression, immune reconstitution, changes in adherence, aging, and 
cumulative exposure to carcinogens.  Understanding these cancer risk patterns is an 
important first step in being able to target screening interventions in HIV patients, and in 
hypothesizing possible etiologic pathways between ART exposure and cancer incidence. 
 The specific characteristics of ART such as antiretrovirals included in the regimen 
and immunologic and virologic response to initiation may be important determinants of 
cancer risk following ART initiation.  However, only a few studies have examined how 
ART-specific characteristics may affect cancer incidence over time.  In a study of a clinical 
trial comparing antiretroviral treatment interruptions to continuous antiretroviral treatment, 
ADC incidence was statistically significantly higher in the antiretroviral treatment 
interruption arm, while NADC incidence did not differ dramatically between the two arms 
though incidence was slightly higher in the treatment interruption arm[63].  A few laboratory 
studies have hypothesized effects of particular antiretrovirals with cancer risk[64-66].  
However, observational studies have not yet resolved whether the contents of ART 
meaningfully affect cancer risk following initiation[67, 68].  Only one study has examined 
the association of virologic and immunologic response after ART initiation with cancer 
incidence which found infection-related NADC incidence to be associated with greater time 
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spent with a CD4 count less than 200 cells/mm3 [69].  Further examination of the 
relationship between ART response and cancer incidence may help elucidate the 
mechanisms through which ART use may impact cancer risk. 
 
E. Summary 
 
 Cancer continues to be a leading contributor to morbidity and mortality in the HIV 
population[5, 6, 70].  While the burden of ADCs has decreased over calendar time, the 
burden of NADCs has increased with the aging HIV population[6].  HIV-infected individuals 
have higher risk than HIV-uninfected individuals for many NADCs, even after accounting 
for behavioral and demographic differences.  Thus HIV infection may have direct effects on 
cancer risk.  Specifically, both immune suppression and ongoing viral replication have 
been hypothesized to impact cancer risk[24, 34, 54].  Because of these hypotheses, ART 
would be expected to reduce NADC incidence, but current studies have shown 
inconsistent associations between ART use and NADC risk.  In fact, the majority of cancer 
diagnoses now occur in HIV patients after the initiation of ART[2, 32, 50]; however, few 
studies have described the trends in cancer risk following ART initiation.  Additionally, only 
one study has examined the effects of immunologic and virologic ART response on 
subsequent NADC incidence. 
 To address the current gaps in the literature, we plan to better characterize the 
relationship of ART and ART response with cancer incidence, by using a comprehensive 
data source and analytic plan that will reduce the limitations present in previous studies. 
 
 
  
  
 
 
III. RESEARCH DESIGN AND METHODS 
 
A.  Study Population 
 
Data was utilized from the CFAR Network of Integrated Clinical Systems (CNICS) to 
better understand the relationship between ART initiation, immunologic and virologic ART 
response, and cancer incidence.  CNICS has extensive information on antiretroviral 
medications, cancer incidence and staging, other medical diagnoses, laboratory 
measurements, demographics, and medications from eight HIV clinics in the United States.  
In total, at the time at which data was acquired for this study CNICS included over 25,000 
HIV-infected patients with over 300 incident cases of NADCs that occurred in patients after 
ART initiation[23].  The population was mostly male (81%), predominantly from urban 
populations, and had a distribution of races representative of the U.S. HIV population[71]: 
39% black, 46% white, 11% Hispanic, and 4% other races.  CNICS enrollment included 
patients who initiated clinical care at one of the eight sites after January 1, 1995, and 
enrollment is continuously ongoing as new patients initiate care at the clinics.  In order to be 
eligible for the study population a patient had to be 18 years of age or older, diagnosed with 
HIV, and the patient must have attended at least two medical visits within twelve months at 
one of the eight sites[72].  The eight sites included HIV clinics at Case Western Reserve 
University; University of Alabama at Birmingham; University of California, San Francisco; 
University of Washington; University of California, San Diego; Fenway Community Health 
Center of Harvard University; University of North Carolina, Chapel Hill; and Johns Hopkins 
University[71, 72].  
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This study population was advantageous because it provided a large, representative 
sample of the United States HIV population in care.  Information was collected as a part of 
normal clinical care through patient medical charts and electronic medical records, and so 
there was very little burden associated with study participation.  As a result, large 
differences between those who participated and those who chose not to participate in the 
study were unlikely.  For example, at the University of North Carolina, Chapel Hill clinic, over 
90% of those asked to participate in the study choose to enroll[73].  CNICS was an ideal 
resource to address our aims as it provided detailed clinical information on a large sample of 
HIV-infected patients.  The CNICS study had also recently verified all cancer diagnoses 
through a standardized protocol (Table III.1).  Because clinical records were available both 
before and after the date of cancer diagnosis, the CNICS study had the ability to perform 
rigorous validation procedures through extensive medical record review on every cancer 
diagnosis occurring while a patient is receiving HIV care at a CNICS clinic.   
 Multiple measures were undertaken to assure the validity of CNICS data, including 
data quality protocols regularly conducted at the CNICS data repository located at the 
University of Washington, Seattle, and checks that were done by our study team to assess 
accuracy and completeness of the data.  At the CNICS data repository, data was regularly 
integrated using a standardized data mapping system for all eight study sites.  Newly 
integrated data was checked for completeness and logical consistencies at the individual 
study sites and at the centralized CNICS repository.  Automated validity checks were 
regularly run on the centralized database. For example, HIV viral load measurements must 
not precede a patient’s HIV diagnosis date.  Data managers at the repository were regularly 
in communication with investigators from each study site, and consulted with individual sites 
to reconcile any inconsistencies or incomplete values in the data[74]. 
For my study, the population included patients who were HIV-1 seropositive, at least 
18 years of age, and who initiated a first ART regimen, defined as the concurrent use of at 
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least three different antiretrovirals, while in the CNICS cohort between 1996 and 2011.  
Patients also had to initiate a first ART regimen before the end of cancer ascertainment at 
their respective CNICS site.  The end dates for cancer ascertainment by site were: Case 
Western Reserve University= 31 May 2010, Fenway Community Health Center= 30 April 
2011, Johns Hopkins University= 31 May 2010, University of Alabama= 30 April 2012, 
University of California-San Diego= 31 May 2010, University of California-San Francisco=31 
August 2011, University of North Carolina= 31 May 2011, and University of Washington=30 
September 2010.  Patients were included who had a cancer diagnosis prior to entry into the 
CNICS cohort, or who had prior exposure to mono- or dual-antiretroviral therapy.  However, 
sensitivity analyses were conducted in which: 1) only patients with no prior history of a 
cancer diagnosis were included and 2) only patients who are antiretroviral naïve at ART 
initiation were included.  For cancer-specific analyses, only patients who had a diagnosis of 
the cancer being studied prior to entry into the CNICS cohort were considered for exclusion.   
 
B.  Exposure Measurement 
 
For this study the main exposure of interest was immunologic response to ART.  For 
the assessment of immunologic response, a novel cumulative measure of 
immunosuppression was developed termed CD4 count-years.  This measure was calculated 
similarly to copy-years viremia, a measure previously developed to capture cumulative viral 
HIV burden. Copy-years viremia is calculated by estimating the area under the curve of 
multiple HIV-1 viral RNA measurements over time utilizing the trapezoidal rule[75, 76].  
Specifically, two consecutive HIV RNA measurements are averaged and multiplied by the 
length of time between the two measurements.  The resulting values from each interval 
between measurements are then summed across time. Copy-years viremia has previously 
been shown to predict the hazard of AIDS or death independently of traditional measures of 
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HIV viremia such as viral set point, peak viral load, and most recent viral load[75].  
Additionally, copy-years viremia following ART initiation in those initiating a first ART 
regimen has been shown to predict death independently of cross-sectional viral load 
measures and time-updated CD4 counts[76].  In this study, CD4 count-years was calculated 
using CD4 count measurements available following ART initiation.  As an example, a patient 
with a CD4 count of 200 cells/mm3 for the first six months after ART initiation and a CD4 
count of 400 cells/mm3 for the next six months was equivalent to a patient with a CD4 count 
of 300 cells/mm3 for one year.   While a few studies have previously explored the 
association of duration of time below 200 CD4 cells/mm3 with cancer incidence, no 
published research has yet examined a measure that accounts for both the extent and 
duration of immunosuppression[32, 69, 77].  The use of CD4 count-years added an 
innovative component to this research plan.  Latest CD4 count, defined as a time-varying 
measure updated every time a patient received a new CD4 count measurement after ART 
initiation, and CD4 count at six months following ART initiation, defined as the most recent 
CD4 count measurement received after ART initiation and before six months post-ART, 
were also considered as traditional measures of time-varying and short-term immunologic 
response, respectively.   
 
C.  Outcome Measures 
 
The primary outcome of interest for all study aims was cancer diagnosis as 
documented in clinical records.  While patterns and associations with specific cancer types 
were explored, this study focused on measures of association with groups of common 
cancers as it was not anticipated that this study would have sufficient power to detect 
associations with specific cancer types.  Cancers were categorized into groups based on 
prior knowledge of common biologic mechanisms in order to ensure the validity of 
   
 
15 
 
inferences drawn from this study and based on prior established categories so as to be 
comparable with past research (Table III.2).  The final cancer groups chosen to highlight in 
the presentation of results were based on prior knowledge and established categories, as 
well as similar patterns seen between individual cancer types in the data. 
 
D.  Other Measures 
 
 A number of other time-fixed and time-varying covariates available in the CNICS 
database were considered as possible confounders or effect measure modifiers of the 
associations between baseline patient characteristics, immunologic ART response, and 
cancer incidence (Table III.3). 
 
 
E.  Statistical Analysis- Aim 1 
 
For the first aim, descriptive analysis of cancer incidence was conducted.  Only the 
first incident cancer following antiretroviral initiation was counted after which the patient was 
censored from the analysis in order to avoid inclusion of recurrent cancers.  Patients were 
also censored at death, loss-to-follow-up (defined as more than 12 months without a CD4 
count or HIV RNA measure), last date of cancer ascertainment by CNICS site (ranging from 
May 31, 2010-Dec. 31, 2011), and administrative censoring at 10 years after ART initiation.  
Incidence rates were calculated over all time after ART initiation, in the first six months after 
ART initiation, and from six months to ten years after ART initiation for each specific cancer, 
all cancers combined, and various cancer groups as defined in Table III.1.  Hazard curves 
over time since ART initiation were constructed and incidence rates were calculated for six-
month and one-year intervals following ART initiation.  This characterized the time periods 
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after ART initiation at which cancer diagnosis was most common, and the timing of NADC 
incidence was contrasted with the timing of AIDS-defining cancers following ART initiation.  
Cox proportional hazard regression was used to estimate associations between cancer 
incidence and patient characteristics at ART initiation, specifically calendar year, CD4 count, 
HIV viral load, age, and prior exposure to antiretrovirals (mono-therapy, dual-therapy, or an 
unknown antiretroviral history). The proportional hazards assumption was tested for each 
patient characteristic by evaluation of the interaction with the log of time since ART initiation.  
In addition, incidence rate trends were assessed stratified by categories of CD4 count and 
HIV viral load laboratory values at ART initiation, as well as categories of calendar year of 
ART initiation, prior antiretroviral exposure, and age at ART initiation.   
We anticipated an initial increase in cancer diagnoses due to increased detection with 
entry into care and ART initiation.  Information gained from this aim was used to inform the 
start of follow-up for Aim 2 in order to avoid this initial detection bias. Additionally, the 
distributions of all other key covariates were examined in order to guide decisions about 
categorization or transformation of covariates later in the analysis.  For all analyses, if the 
results of cancer-specific analyses indicated different associations within cancer groups, 
different possible cancer categorizations were considered.  As mentioned earlier, sensitivity 
analyses were conducted in which patients with a cancer diagnosis or antiretroviral 
exposure prior to ART initiation were excluded.  Results in these subpopulations were 
compared to those observed in the total population.  We performed all analyses in SAS 
version 9.2[78]. 
 
F.  Statistical Analysis-  Aim 2 
 
 For the second aim, survival analysis methods were used to estimate the association 
of immunologic ART response with NADC incidence.  Cox proportional hazards regression 
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models were used to estimate hazard ratios and 95% confidence intervals.  The proportional 
hazards assumption was evaluated by inclusion of an interaction term with the log of time 
since ART initiation in the model.  Immunologic response as a predictor of NADC incidence 
was assessed starting from ART initiation.  Follow-up for cancer incidence began at six 
months after ART initiation in order to exclude the excess of cancers initially detected due to 
increased medical attention following ART initiation, and in order to allow time for 
measurement of the initial immunologic and virologic response.  Patients were followed until 
the first of NADC diagnosis, death, loss-to-follow-up, last date of cancer ascertainment by 
CNICS site, or administrative censoring at 10 year after ART initiation.   
 Potential confounders were considered based on previous knowledge of 
mechanisms and etiologic pathways for both HIV and cancer.  Confounders were assessed 
in multivariable regression models by evaluating the change-in-estimate and the increase in 
precision produced from removing each confounder from the model.  Covariates that 
produced a change-in-estimate of greater than or equal to 10% were considered important 
confounders to be included in the model.  An appropriate set of confounders was selected 
separately for each regression model.   
HIV viral load can act as a time-varying confounder affected by prior immunologic 
response that cannot be accounted for using traditional adjustment methods.  As such, 
marginal structural models that apply inverse probability weights to remove confounding 
without blocking causal effects were used to disentangle the effects of the immunologic and 
virologic components of ART response[79-81].  Specifically, linear regression models were 
used to calculate the probability that a patient would have the CD4 count that was observed 
based on the HIV RNA measurements from their prior two clinical visits.  These probabilities 
were calculated for each CD4 count observed after ART initiation, and the inverse of these 
probabilities was used to weight each observation in the final regression model.  In order to 
stabilize these weights, numerators were calculated equal to the probability of the observed 
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CD4 count measurement given time-fixed covariates, and the same time-fixed covariates 
were used in the calculation of the probabilities used for the denominator of the weights.  
Specifically, time-fixed covariates used to stabilize weights were: CD4 count at ART 
initiation, HIV RNA at ART initiation, injection drug use transmission risk, men who have sex 
with men transmission risk, prior antiretroviral use, race, calendar year of ART initiation, and 
age at ART initiation.  Inverse-probability-of-censoring weights were calculated to account 
for differential censoring by time-varying HIV viral load, in which the weights were equal to 
the inverse of the probability that a patient would be censored given the HIV RNA 
measurement from their two prior clinical visits.  Additionally, inverse-probability-of-
frequency weights were applied to account for differences in the frequency of CD4 count 
measurements in different patient groups[82, 83], in which weights were applied that were 
equal to the inverse of the probability of receiving a CD4 count measurement within each 
one week interval following ART initiation.  After each of these three set of weights were 
calculated, total weights were calculated by multiplying together the three weights for each 
observation.  The total weights were applied to the final regression models used to assess 
the relationship between immunologic response and NADC incidence.  The same weights 
were used for assessment of each measure of immunologic response. 
These analyses were also repeated with the use of exposure lags to account for the 
empirical induction period between immunologic ART response and NADC diagnosis[84].  
Exposure lagging was implemented by only including exposures that have occurred a 
certain time period prior to the time of outcome assessment.  In our analysis we explored 
six-month and twelve-month exposure lags in which only CD4 counts occurring more than 
six or more than twelve months before cancer ascertainment, respectively, were used as a 
part of our measures of immunologic ART response.  For six month lag analyses, follow-up 
time started at twelve months after ART initiation to allow time for an initial immunologic 
response and six months of lag time.  Likewise, for twelve month lag analyses, follow-up 
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time started at eighteen months after ART initiation to allow for an initial immunologic 
response and twelve months of lag time.  Multiple time lengths were explored as these 
methods can be sensitive to assumptions about the length of the lag time.   
This analysis was repeated for cancer groups as previously defined (Table III.1), as 
well as for specific common NADC diagnoses such as lung cancer and anal cancer.  As 
competing risks, such as death, may likely be associated with ART use, sensitivity analysis 
was also conducted in which we assessed the impact of observing various patterns of 
cancer incidence in the absence of death[85].   
 
   
 
  
   
 
20 
 
Table III.1 Incident cancer cases among HIV-infected patients treated for at least six months 
with ART in the CNICS cohort between 1996 and 2009, from Achenbach et al., 2011. 
Cancer Diagnoses N (%) 
     Kaposi’s sarcoma 185 (29) 
     Non-Hodgkin’s Lymphoma non-CNS 114 (18) 
     Lung 59 (9) 
     Anal 55 (8) 
     Hodgkin’s Lymphoma 32 (5) 
     Prostate 27 (4) 
     Non-Hodgkin’s Lymphoma CNS 22 (3) 
     Liver 22 (3) 
     Kidney 19 (3) 
     Melanoma 15 (2) 
     Breast 11 (2) 
     Colorectal 11 (2) 
     Othera 78 (12) 
Summary Cancer Diagnoses 
 
     Infection-unrelated NADCs 221 (34) 
     ADCsb 321 (49) 
     Infection-related NADCsc 108 (17) 
aOther cancers: cervical, biliary, bladder/urinary, primary brain, esophagus, oral cavity/pharynx, 
other head and neck, leukemia, multiple myeloma, other (not specified or unknown origin), ovary, 
pancreas, penis, peritoneum/retroperitoneum, small intestine, soft tissue, stomach, testicular, 
thyroid, trachea/pleura, uterus, and vagina/vulva. 
bADCs: cervical, Kaposi’s sarcoma, and Non-Hodgkin’s lymphoma. 
cInfection-related NADCs: squamous cell anal, squamous cell oral cavity/pharynx, Hodgkin’s 
lymphoma, liver with viral hepatitis, vagina/vulva, and penis.  
ART=combination antiretroviral therapy, CNICS= CFAR Network of Integrated Clinical Systems, 
CNS=central nervous system, NADCs= Non-AIDS-defining cancers, ADCs=AIDS-defining 
cancers 
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Table III.2 Categories for grouping cancer diagnosis outcomes 
Category Name Cancers within Category 
AIDS-defining cancers Kaposi sarcoma, non-Hodgkin lymphoma, 
cervical cancer 
Non-AIDS-defining cancers All cancers not included as AIDS-defining 
Virus-related cancers Kaposi sarcoma, non-Hodgkin lymphoma, 
cervical cancer, anal cancer, Hodgkin 
lymphoma, liver cancer in the presence of 
hepatitis, squamous cell oral cavity/pharynx, 
vagina/vulva cancer, penis cancer 
Virus-unrelated cancers All cancers not included as virus-related (lung 
cancer, prostate cancer, colorectal cancer, etc.) 
Virus-related non-AIDS-defining cancers Anal cancer, Hodgkin lymphoma, liver cancer 
in the presence of hepatitis, squamous cell oral 
cavity/pharynx, vagina/vulva cancer, penis 
cancer 
Lymphomas Non-Hodgkin lymphoma and Hodgkin 
lymphoma 
HPV-related cancers Anal cancer, cervical cancer, squamous cell 
oral cavity/pharynx cancer, vagina/vulva 
cancer, penis cancer 
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Table III.3 Study Variable Descriptions 
Variable Name Description Type 
Outcome 
Cancer New cancer diagnosis as indicated 
by medical records with cancers 
grouped as stated in Table 2 
Binary, Time-to-First-
Event 
Primary Exposures 
CD4 count loss-years  Cumulative measure of 
immunosuppression incorporating 
the CD4 count loss below 500 
cell/mm3 and duration of exposure 
starting at ART initiation 
Continuous, Time-
varying 
 Other Exposure Measures  
Latest CD4 count Most recent measure of CD4 count 
prior to each time point following 
ART initiation 
Continuous, Time-
varying 
Six month CD4 count Most recent CD4 count following 
ART initiation, but prior to six month 
after ART initiation 
Continuous, Time-
fixed 
Covariates 
Baseline CD4 count Most recent CD4 count prior to ART 
initiation 
Continuous 
Baseline Viral Load Most recent viral load prior to ART 
initiation 
Continuous 
Viral load at 24 weeks HIV viral load nearest to 24 weeks 
after ART initiation within a window 
of 12-36 weeks after ART initiation 
Continuous, Time-
fixed 
Most recent viral load Most recent measure of HIV viral 
load prior to each time point 
following ART initiation 
Continuous, Time-
varying 
Sex Male or Female. Transgendered 
patients not included in analysis 
Binary 
Age Age at ART initiation in years Continuous 
Race White, Black, Hispanic, or Other Categorical 
IDU Injection drug user. Identified 
injection drug use as a HIV 
transmission risk 
Binary 
MSM Men who have sex with men. Man 
who identified sex with men as a HIV 
transmission risk  
Binary 
Calendar Year Calendar year of ART initiation 
centered at 1996 
Continuous 
CNICS site Indicator of which of the eight CNICS 
clinical sites patient was attending at 
the time of ART initiation 
Categorical 
Type of Antiretroviral 
Regimen 
Categorized by regimen backbone 
as: non-nucleoside reverse 
transcriptase inhibitor, protease 
inhibitor, triple nucleoside reverse 
Categorical 
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transcriptase inhibitor regimen, or 
other regimen.  Binary variables may 
also be derived from ART 
information to indicate the presence 
or absence of certain antiretrovirals, 
such as AZT, in the ART regimen. 
BMI Calculated based on height and 
weight measurements made nearest 
to ART initiation date using the 
formula: [Weight 
(lb.)*703]/[height(in)2] 
Continuous 
AIDS-defining condition Diagnosis of an AIDS-defining 
condition (yes vs. no). When AIDS-
defining cancers are included as an 
outcome, this variable will only 
include non-cancer AIDS-defining 
conditions. 
Binary, Time-varying 
Hepatitis B Categorized as never infected vs. 
ever infected.  Positive laboratory 
results for Hepatitis B core Antibody, 
Hepatitis B surface antigen, or 
Hepatitis B DNA. 
Binary, Time-varying 
Hepatitis C Categorized as never infected vs. 
ever infected.  Positive laboratory 
results for Hepatitis C Antibody or 
Hepatitis C RNA. 
Binary, Time-varying 
 
 
 
  
  
 
 
IV. RESULTS:  INCIDENCE AND TIMING OF CANCER FOLLOWING INITIATION OF 
COMBINATION ANTIRETROVIRAL THERAPY, IN THE UNITED STATES 1996-
2011 
 
A. Introduction 
 
 While the distribution of cancer types within HIV-infected populations has changed 
due to advances in treatment and demographic changes, malignancies remain a leading 
cause of morbidity and mortality[1, 5, 6].  Cancer incidence trends in the HIV population 
have been thoroughly examined across calendar time[1, 16, 57, 60].  However, incidence 
rates among HIV patients are not well-described across time relative to initiation of 
combination antiretroviral therapy (ART), even though most cancers are diagnosed after the 
initiation of ART[2, 32, 50].    
Given the many changes in patient characteristics that occur after ART initiation, 
including immune reconstitution, HIV replication, aging, and ongoing exposure to 
carcinogens, cancer incidence over time following ART initiation is expected to be dynamic.  
Additionally, improvements in access to HIV testing and linkage to care as well as changes 
in the timing of ART initiation may impact the timing and incidence of cancer diagnoses in 
treated patients.  In a large, diverse U.S. HIV cohort collaboration, the CFAR Network of 
Integrated Clinical Systems (CNICS), we evaluated trends in cancer incidence rates over 
time after ART initiation to inform cancer screening and prevention efforts for the HIV 
population in the ART era.  We further identified patient characteristics associated with 
these trends that may provide insights into the etiology of cancers occurring in HIV-infected 
populations.   
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B. Methods 
 
Study Population 
This study used data from the CNICS, a collaboration of eight HIV clinic sites that 
collect information on patients engaged in routine HIV clinical care.  CNICS captures 
extensive and comprehensive electronic medical data, including demographics, 
medications, co-morbid diagnoses, and laboratory values[72].  CNICS includes over 25,000 
patients who have initiated clinical care at one of the eight sites between January 1, 1995 
and the present.  Within this cohort, cancer diagnoses are verified through a standardized 
process[23]. 
For our study, we included all patients who initiated ART with a known start date 
between Jan. 1, 1996-Aug. 30, 2011, and who had baseline CD4 count and HIV RNA 
measurements at ART initiation.  Baseline CD4 count and HIV RNA measures were values 
most proximal to, but no more than 12 months before, ART initiation.  ART was defined as 
concurrent initiation of at least three different antiretrovirals. For our primary analyses, we 
included patients with prior exposure to one or two nucleoside/nucleotide agents (mono- and 
dual-antiretroviral therapy, respectively) or who had an unknown antiretroviral history prior to 
initiating ART. We did not analyze person-time prior to ART initiation; however, we did 
assess effects of prior therapy exposure on our results, and conducted sensitivity analyses 
in which only patients who were antiretroviral-naive at ART initiation were included.   
Patients were followed from ART initiation to the first of the following: cancer 
diagnosis, death, loss-to-follow-up (defined as 12 months without a clinical visit), or 
administrative censoring at the last date of cancer ascertainment for each clinic site (range 
of May 31, 2010-Aug. 31, 2011).  Follow-up time was administratively censored at 10 years 
after ART initiation, at which point <10% of the patients remained under observation.  Only 
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the first cancer diagnosis after ART initiation was included as an event.  In our primary 
analyses we included all patients initiating ART without regard to cancer events prior to ART 
initiation. To assess the influence of including patients with a previous history of cancer, we 
performed sensitivity analyses in which patients with cancer diagnoses prior to ART initiation 
were excluded. 
 
Statistical Analysis 
Incidence rates (IRs) were estimated as the total number of cancer diagnoses within 
the time interval divided by the total number of person-years contributed within the same 
interval.  Overall cancer incidence rates and incidence rates within 6-month and 1-year time 
intervals following ART initiation were calculated for specific cancers as well as for clinically 
meaningful pre-defined groups of cancers.  Specifically, we assessed incidence rates for 
cancers using different categorizations including: AIDS-defining cancers (ADCs), non-AIDS-
defining cancers (NADCs), lymphomas, HPV-related cancers (including cervical, anal, 
squamous cell oral cavity/pharynx, vagina/vulva, and penis cancer), virus-related cancers 
(including all ADCs, all HPV-related cancers, Hodgkin lymphoma, and liver cancer), and 
virus-unrelated cancers. 
Poisson regression was used to contrast incidence rates between time intervals and 
to estimate trends in incidence rates across time following ART initiation.  Baseline clinical 
characteristics were examined with Cox regression to identify predictors of cancer incidence 
following ART initiation.  Cancers were grouped by common etiology and similar incidence 
patterns over time when assessing associations with baseline characteristics.  Multivariable 
analyses were conducted with adjustment for all baseline demographic and clinical 
predictors determined to be associated with cancer incidence based on a priori knowledge.  
Two separate adjustment sets were used: one with CD4 count at ART initiation, and one 
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with nadir CD4 count any time prior to ART.  These two variables were not included 
simultaneously as they were highly correlated, but were included separately to examine 
whether choice of CD4 measure affected other estimates differentially, especially for 
patients with prior antiretroviral exposure.  Stratified incidence rates across time were also 
calculated by CD4 count at ART initiation (≥ or <200 cell/mm3), age (≥ or <45), and prior 
exposure to antiretrovirals.  Changes in the associations of these predictors with cancer 
incidence were assessed visually, and through the evaluation of interaction terms with 
log(time) in regression models.   
 
C. Results 
 
Baseline Characteristics 
Of 25,337 patients enrolled in CNICS at the time of this analysis, 11,485 were 
observed to initiate ART between 1996 and 2011 at a CNICS site with pre-ART CD4 count 
and HIV RNA levels available.  Of these 11,485 patients, 20% were female, 43% were 
white, 41% black, and 11% Hispanic (Table 4.1). Median age at ART initiation was 38 years 
(interquartile range [IQR]: 32-45). Twenty-eight percent of patients had exposure to 
antiretrovirals prior to ART initiation, and the median year of ART initiation was 2004 (IQR: 
2000-2007).  At ART initiation median CD4 count was 202 cells/mm3 (IQR: 61-338) and 
median HIV RNA was 4.8 log10 copies/mL (IQR: 4.3-5.3).  Most patients initiated a PI-based 
regimen (47%), of which 26% included atazanavir/ritonavir and 21% included 
lopinavir/ritonavir, or a NNRTI-based regimen (42%), of which 90% included efavirenz.  In 
addition, 5% initiated a triple-NRTI regimen, 4% initiated a regimen with a PI and an NNRTI, 
and 2% initiated with another anchor drug, including integrase inhibitor, fusion inhibitor, and 
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entry inhibitor regimens.  The median length of follow-up after ART initiation was 3.1 years 
(IQR: 1.4-6.2) with only 9.5% of patients remaining in follow-up at 10 years post-ART. 
 
Cancer Incidence and Timing  
 During the 46,318 years of follow-up after ART initiation, 457 cancer diagnoses were 
observed with an IR of 987 cases per 100,000 person-years (95% Confidence Interval 
[CI]:900-1081) (Table 4.2). The overall incidence of ADCs was similar to that of NADCs 
(ADC IR: 515 per 100,000 person-years, 95%CI: 454-584; NADC IR: 466 per 100,000 
person-years, 95% CI: 408-533). The most common ADC was KS with an IR of 304 per 
100,000 person-years (95% CI: 258-358), while the most common NADC was anal cancer 
with an IR of 69 per 100,000 person-years (95% CI: 49-98).  Among women, the most 
common NADC was breast cancer (IR: 128 per 100,000 person-years; 95%CI: 75-221).   
The timing of cancer incidence after ART initiation differed between cancer types.  
KS had a particularly high incidence within the first 6 months (IR: 1342 cases per 100,000 
person-years, 95%CI: 1071, 1683), but incidence decreased dramatically afterwards (IR for 
second 6 months: 348 per 100,000 person-years, 95% CI: 219-552) and stabilized at a low 
rate (IR for 6 months-10 years: 164 per 100,000 person-years, 95% CI: 129, 208) (Table 
4.2, Figure 4.1).  Lymphomas (both Hodgkin and non-Hodgkin) also occurred at a higher 
incidence in the first 6 months post-ART initiation (IR: 660 per 100,000 person-years, 95% 
CI: 479-912) compared to 6-12 months after ART initiation (IR: 269 per 100,000 person-
years, 95% CI: 160-455), but the absolute change in incidence was smaller than for KS. By 
contrast, incidence rates of other cancers appeared to progressively increase with time after 
ART initiation.  When combined, all non-KS, non-lymphoma cancers had incidence rates 
that increased by 7% each year from ART initiation (95% CI: 2%-13%; p=0.009), from 416 to 
615 cases per 100,000 person-years in years 1 and 10 post-ART initiation respectively.  
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Predictors of Cancer Incidence and Time-Modification of Predictors 
Several characteristics at the time of ART initiation had distinct relationships with 
subsequent cancer incidence.  Older age increased risk for all cancers except KS in 
bivariable analyses, and associations appeared the same in multivariable analyses (Table 
4.3). Non-lymphoma, HPV-unrelated NADCs were most strongly associated with older age 
(adjusted HR for 10 year difference in age: 2.33, 95% CI: 1.97-2.74).  Associations of older 
age with cancer risk were consistent throughout time following ART initiation (P for 
interaction with time>0.05 for all cancers) (Figure 4.2).   
CD4 count at ART initiation was the other consistent predictor of cancer incidence.  
Both in bivariable and multivariable analyses, lower CD4 counts were associated with higher 
cancer incidence for all cancer groups except the non-lymphoma, HPV-unrelated NADCs.  
Lower CD4 count was a particularly strong predictor of incidence of KS (Adjusted HR per 
100 cells/mm3 increase: 0.63, 95%CI: 0.54-0.73).  The pattern of high KS incidence within 
the first six months followed by a steep decline in incidence was only seen among those 
with a CD4 count <200 cells/mm3 at ART initiation (Figure 4.3, P for interaction of CD4 count 
with time =0.002).  By contrast, those with a CD4 count ≥200 cells/mm3 had low incidence of 
KS throughout time after ART initiation (IR: 0.1 per 100 person-years, 95%CI: 0.1-0.2).  Low 
CD4 count was also associated with high incidence of lymphomas and HPV-related 
cancers, but for these cancers, associations with CD4 count were consistent across time 
(both P for interaction of CD4 count with time>0.20) (Figure 4.3).   
Prior exposure to antiretrovirals was also associated with higher incidence of HPV-
related cancer following ART initiation.  This association persisted even when nadir CD4 
count was included in the model in place of CD4 count at ART initiation.  Across all follow-up 
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time, prior antiretroviral exposure was not associated with incidence of other cancers.  
However, for lymphomas, patients with prior antiretroviral exposure had lower incidence 
compared to antiretroviral naïve patients in the first year following ART initiation (Adjusted 
HR: 0.41, 95%CI: 0.19-0.93), but higher incidence than antiretroviral naïve patients after one 
year (P for interaction with time <0.05) (Figure 4.4).   
Other characteristics examined were weaker predictors of cancer incidence. Higher 
levels of HIV RNA prior to ART were associated with higher KS incidence, but not with any 
other cancer after adjusting for CD4 count.  No statistically significant associations were 
found between calendar year of ART initiation and incidence of any cancers in bivariable 
analysis.  After accounting for variables such as age and CD4 count at ART initiation, there 
was no association between calendar year and any cancer (Table 4.3).  The lack of 
association was robust to parameterization of calendar year as a continuous or categorical 
variable. 
In sensitivity analysis where 489 patients with cancer diagnoses prior to ART 
initiation were excluded, similar incidence rates and incidence trends were observed and the 
same predictors of cancer incidence were identified (data not shown). Similarly, our findings 
were consistent in a subset analysis conducted among 8278 patients who were antiretroviral 
naïve at ART initiation.  In this subset incidence rates and trends were similar to the full 
study population and factors associated with higher risk were also consistent in both 
unadjusted and adjusted analyses (data not shown).   
 
D. Discussion 
 
This study of 11,485 patients from a multi-site U.S. clinical cohort of HIV-infected 
patients followed up to 10 years revealed distinct patterns of cancer incidence following ART 
initiation.  This likely reflects varying etiologic contributions of aging, immunosuppression, 
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and prior antiretroviral exposure, to the occurrence of specific cancer types.  By contrast, 
cancer incidence did not appear to change over calendar time among ART initiators 
suggesting that the incremental improvements in ART regimens during the modern ART era 
have not had dramatic effects on cancer incidence. 
The most dramatic change in incidence after ART initiation was seen for KS, which 
exhibited an incidence higher than all other cancers combined in the first six months and a 
steep decline thereafter.  A similar pattern has been noted in ART initiators in the Swiss HIV 
Cohort Study[86].  Upon stratification by CD4 count at ART initiation, this incidence pattern 
was exclusively seen in those initiating with a CD4 count less than 200 cell/mm3.  This 
observation mirrors results from the HIV/AIDS Cancer Match Study, which demonstrated 
that severe immunosuppression at AIDS diagnosis was most strongly associated with KS 
risk in the first six months after AIDS diagnosis, and less strongly thereafter[87]. This finding 
and prior research demonstrating higher KS incidence among those with lower current CD4 
counts[3, 17, 32, 88] are consistent with an early risk driven by more severe 
immunosuppression. In addition to severe immunosuppression increasing the risk of KS 
development, these individuals are more likely to experience more rapid immune 
reconstitution that may unmask previously subclinical KS, a phenomenon referred to as 
immune reconstitution inflammatory syndrome (IRIS)[51, 89-91].   
Lymphomas showed a pattern similar to KS, but with a lower incidence in the first six 
months and a more gradual decrease in incidence thereafter.  A decrease in incidence after 
six months was seen in both Non-Hodgkin lymphomas and Hodgkin lymphomas.  
Individuals with no prior antiretroviral exposure and those with lower CD4 counts at ART 
initiation had higher lymphoma incidence within the first six months.  Similar to KS, these 
patient groups may be more likely to develop lymphoma associated IRIS events after ART 
initiation.  An IRIS effect for lymphoma was hypothesized after a study in France showed a 
similar incidence pattern when looking at Hodgkin’s lymphoma after ART[50].  It is also 
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possible that early symptoms of subclinical KS or lymphoma may have led to the HIV 
diagnosis and prompt initiation of ART, with eventual documentation of the definitive cancer 
diagnosis shortly after starting ART.  Regardless, these findings highlight the importance of 
early HIV diagnosis and timely ART initiation before individuals reach advanced 
immunosuppression.  
All other cancers combined showed an increasing trend over time following ART 
initiation with a lower incidence within the first six months and a significant trend toward 
higher incidence over time.  This increase is likely a consequence of increasing cancer 
incidence with advancing age, as noted in the general population. Within this group of 
cancers that excluded KS and lymphoma, HPV-related cancers showed a strong association 
with CD4 count at ART initiation and higher incidence in those with prior antiretroviral 
exposure, which may reflect longer duration of HIV infection. As HIV infection can increase 
the risk of HPV infection, a lag in time may occur before the increased risk is manifest as 
increased cancer diagnosis rates in patients with a longer duration of HIV infection[18, 24, 
42, 61].  It is also possible that adjustment for nadir CD4, a risk factor for HPV-associated 
cancers[2, 16, 26, 42], was inadequate if patients with prior antiretroviral exposure 
experienced their nadir CD4 before entry into a CNICS clinic.  We did not observe an 
association between CD4 count at ART initiation and incidence of cancers that are neither 
AIDS-defining or associated with viral infections.  Others have shown some virus-unrelated 
NADCs to be associated with the extent of immune suppression[17, 53].  A larger sample 
size may be needed to observe an association between low CD4 count and virus-unrelated 
NADCs; however, our data suggest that the relationship is not particularly strong. 
Previous studies have described changing trends in cancer incidence within the HIV 
population as a whole[16, 60, 70]; however, in our population of ART initiators no changes in 
cancer incidence were observed over calendar time.  Our study included more recent 
calendar years of follow-up than previous studies, and 75% of patients initiated ART in the 
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year 2000 or later. Trends identified in the larger HIV population are likely indicative of 
increased uptake of ART, while more recent changes in the potency or durability of first-line 
ART regimens[92] may have little impact on cancer incidence.  This emphasizes the 
continued need for cancer screening and prevention measures in the HIV population, 
regardless of continued improvements in ART. 
While our sample size was considerable, there were not enough incident cancer 
cases to conduct separate analyses for all specific cancer types.  While we aimed to 
categorize cancers in etiologically meaningful ways, there may be differing trends for 
cancers grouped together that were undetectable in our study, particularly within the 
heterogeneous group of non-lymphoma, non-HPV-related, NADCs.   Additionally, even 
within specific cancer types malignancies may have different etiologic origins.  Such is the 
case with oral cavity/pharynx cancers and non-Hodgkin lymphomas, in which only a 
proportion are linked to viral co-infection (HPV and EBV, respectively).  Despite this 
limitation, such groupings were necessary in order to discern meaningful trends and 
associations and can be used to guide more detailed analyses in the future.   
This study was notable for the following strengths: a) a large and representative HIV-
infected clinical population; b) detailed laboratory and antiretroviral information; and c) well-
validated cancer diagnoses. The current study does not account for changes or 
discontinuations in ART after initiation nor does it account for differences in the immunologic 
or virologic responses to ART.  In a future study we will examine how these changes after 
ART initiation may impact cancer incidence to expand on these findings and further our 
understanding of cancer incidence trends over time in this population. 
We showed distinct patterns of cancer incidence after ART initiation that differed by 
cancer type and were modified by several baseline patient characteristics.  These findings 
highlight the importance of cancer screening and cancer prevention efforts throughout the 
course of HIV clinical care for those cancers for which evidence-based interventions exist.  
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Currently, robust cancer screening and prevention guidelines have not been established that 
address the specific needs of HIV-infected individuals.  Within the first year after ART 
initiation, KS and lymphomas are the largest sources of cancer morbidity.  After the first year 
of ART initiation, HPV-associated cancer (particularly anal cancer) and other NADCs 
become more common.  These results suggest that screening for HPV-associated cancers 
and certain NADCs should be prioritized once patients are on stable ART.   
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Table IV.1 Demographic and clinical characteristics of 11,485 patients initiating combination 
antiretroviral therapy in the CFAR Network of Integrated Clinical Systems, 1996-2011 
Characteristic N (%) 
Total 11485 
Female Sex 2304 (20.1%) 
Age† 38 (32-45) 
Race 
 
     White 4933 (43.0%) 
     Black 4677 (40.7%) 
     Hispanic 1273 (11.1%) 
     Other/Unknown 602 (5.2%) 
Injection drug user 2156 (18.8%) 
Men who have sex with men 6328 (55.1%) 
Antiretroviral exposure prior to first ART 3207 (27.9%) 
ART initiation year† 2004 (2000-2007) 
ART regimen type 
 
     PI 5443 (47.3%) 
     NNRTI 4835 (42.1%) 
     3+ NRTI 570 (5.0%) 
     NNRTI+PI 441 (3.8%) 
     Other‡ 196 (1.7%) 
CD4 count (cells/mm3)† 202 (61-338) 
HIV RNA level (log10 copies/mL)† 4.8 (4.3-5.3) 
†Median (IQR) given instead of N (%) 
‡includes regimens with an integrase inhibitor, fusion inhibitor, or entry inhibitor 
ART=combination antiretroviral therapy, PI=protease inhibitor, NNRTI=non-nucleoside reverse 
transcriptase inhibitor, NRTI=nucleoside reverse transcriptase inhibitor 
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Table IV.2 Cancer incidence rates within 10 years after combination antiretroviral therapy initiation, CFAR Network of Integrated 
Clinical Systems 1996-2011 
Cancer Type 
Total N 
Incidence rate per 100,000 person-years (95% CI) 
 0-10 years 0-6 months 6 months-10 years 
Overall 457 987 (900-1081) 2405 (2030-2848) 793 (711-884) 
ADC 241 515 (454-584) 1881 (1554-2278) 330 (279-390) 
         KS 143 304 (258-358) 1342 (1071-1683) 164 (129-208) 
         NHL non-CNS 76 161 (128-201) 357 (230-553) 134 (103-175) 
         NHL CNS 19 40 (26-63) 160 (84-308) 24 (13-44) 
         Cervical† 3 30 (10-92) - - 
NADC 216 466 (408-533) 520 (362-749) 459 (398-530) 
    Virus-related NADCs 89 192 (156-237) 251 (149-424) 184 (147-231) 
         Squamous cell anal 32 69 (49-98) 72 (27-191) 69 (47-100) 
         Hodgkin lymphoma 27 58 (40-85) 144 (72-287) 47 (30-73) 
         Liver 17 37 (23-59) 18 (3-127) 39 (24-64) 
         Squamous cell oral cavity/pharynx 9 19 (10-37) - - 
         Other‡ 4 9 (3-23) - - 
    Virus-unrelated NADCS 127 274 (230-326) 269 (162-447) 275 (228-331) 
         Lung 26 56 (38-82) 54 (17-167) 56 (38-85) 
         Prostate† 20 54 (35-83) 22 (3-159) 58 (37-91) 
         Breast† 13 128 (75-221) 177 (44-708) 122 (68-221) 
         Melanoma 10 22 (12-40) - - 
         Colorectal 8 17 (9-35) - - 
         Kidney 5 11 (5-26) - - 
         Other* 45 93 (69-125) - - 
Lymphomas†† 122 259 (217-309) 660 (479-912) 205 (165-253) 
HPV-related cancers‡‡ 48 104 (78-138) 108 (48-140) 103 (76-140) 
†Cervical cancer and breast cancer incidence calculated only among women. Prostate cancer incidence calculated only among men. 
‡Other virus-related cancers include penis, vaginal, and vulva 
*Other virus-unrelated cancers include bladder, brain, esophagus, larynx, leukemia, multiple myeloma, ovary, pancreas, peritoneum, small 
intestine, soft tissue, stomach, testicular, uterus, or non-squamous cell oral cavity/pharynx 
††Lymphomas included NHL non-CNS, NHL CNS, and Hodgkin lymphoma. 
‡‡HPV-related cancers included cervical, squamous cell anal, squamous cell oral cavity/pharynx, penis, vaginal, and vulva cancer 
Only overall incidence rates were calculated for cancer types with ≤10 cases. 
ADC=AIDS-defining cancer, KS=Kaposi’s sarcoma, NHL=non-Hodgkin’s lymphoma, CNS=central nervous system, NADC=non-AIDS-defining 
cancer, HPV=human papillomavirus 
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Table IV.3 Patient characteristics at combination antiretroviral therapy initiation associated with incidence of first cancer stratified by 
cancer type, CFAR Network of Integrated Clinical Systems, 1996-2011 
 
Bivariable Multivariable† 
 
Hazard Ratio (95% CI) 
Kaposi’s Sarcoma 
Age at ART initiation (per 10 year increase) 1.00 (0.84-1.19) 0.99 (0.82-1.21) 
Calendar year of starting ART 1.03 (0.99-1.07) 1.01 (0.97-1.07) 
Prior mono- or dual-therapy 1.00 (0.70-1.43) 1.34 (0.91-1.99) 
CD4 count (per 100 cells/mm3) 0.64 (0.56-0.73) 0.63 (0.54-0.73) 
Viral load (per log10 copies/ml) 1.79 (1.42-2.27) 1.31 (1.01-1.70) 
Lymphomas 
Age at ART initiation (per 10 year increase) 1.29 (1.07-1.55) 1.30 (1.07-1.58) 
Calendar year of starting ART 0.98 (0.93-1.03) 0.97 (0.91-1.02) 
Prior mono- or dual-therapy 0.95 (0.64-1.41) 0.86 (0.55-1.33) 
CD4 count (per 100 cells/mm3) 0.81 (0.72-0.91) 0.80 (0.71-0.91) 
Viral load (per log10 copies/ml) 1.07 (0.85-1.36) 0.85 (0.65-1.11) 
HPV-related cancers 
Age at ART initiation (per 10 year increase) 1.33 (0.99-1.79) 1.41 (1.04-1.93) 
Calendar year of starting ART 0.96 (0.88-1.04) 1.00 (0.91-1.10) 
Prior mono- or dual-therapy 2.33 (1.32-4.13) 2.67 (1.41-5.04) 
CD4 count (per 100 cells/mm3) 0.83 (0.69-0.99) 0.80 (0.65-0.97) 
Viral load (per log10 copies/ml) 1.13 (0.78-1.65) 1.05 (0.69-1.61) 
Non-lymphoma, HPV-unrelated NADCs 
Age at ART initiation (per 10 year increase) 2.34 (2.01-2.74) 2.33 (1.97-2.74) 
Calendar year of starting ART 1.01 (0.96-1.06) 1.00 (0.95-1.06) 
Prior mono- or dual-therapy 1.19 (0.85-1.69) 1.15 (0.78-1.70) 
CD4 count (per 100 cells/mm3) 0.99 (0.91-1.07) 0.99 (0.89-1.09) 
Viral load (per log10 copies/ml) 0.95 (0.77-1.18) 0.93 (0.73-1.19) †Multivariable analyses adjusted for other covariates listed as well as CNICS study site, sex/MSM, race, and IDU 
ART=combination antiretroviral therapy, MSM=men who have sex with men, IDU=injection drug user, HPV=human papillomavirus, NADC=non-
AIDS-defining cancer 
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Figure IV.1 Incidence of first cancer across time following initiation of combination antiretroviral therapy (ART), CFAR Network of 
Integrated Clinical Systems, 1996-2011. 
After ART initiation, incidence rates were estimated in the first six months, the second six months, and every year thereafter.  The vertical lines 
extending from each incidence rate estimate represent the 95% confidence interval.  Listed below the x-axis are the total numbers of patients 
remaining in follow-up at the end of each year. Solid line with circles=Kaposi sarcoma incidence; Dashed line with squares=Lymphoma incidence; 
Dotted line with triangles=Incidence of non-Kaposi sarcoma, non-lymphoma cancers.  KS=Kaposi sarcoma, ART=combination antiretroviral 
therapy. 
3
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Figure IV.2 Cancer incidence across time following initiation of combination antiretroviral therapy (ART) stratified by age at ART 
initiation, CFAR Network of Integrated Clinical Systems 1996-2011. 
Graphs divided by cancer type: (A) Kaposi sarcoma, (B) Lymphoma, (C) HPV-related cancer, (D) Other cancers. Dotted lines with 
diamonds=incidence rates among those 40 years of age or older at ART initiation. Dashed lines with squares=incidence rates among those 
younger than 40 years of age at ART initiation. *Other cancers include lung, liver, prostate, breast, melanoma, colorectal, kidney, bladder, brain, 
esophagus, larynx, leukemia, multiple myeloma, ovary, pancreas, peritoneum, small intestine, soft tissue, stomach, testicular, uterus, or non-
squamous cell oral cavity/pharynx 
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Figure IV.3 Cancer incidence across time following initiation of combination antiretroviral therapy (ART) stratified by CD4 count at 
ART initiation, CFAR Network of Integrated Clinical Systems 1996-2011. 
Graphs divided by cancer type: (A) Kaposi sarcoma, (B) Lymphoma, (C) HPV-related cancer, (D) Other cancers. Dotted lines with 
diamonds=incidence rates among those with CD4 counts less than 200 cells/mm3 at ART initiation. Dashed lines with squares=incidence rates 
among those with CD4 counts greater than or equal to 200 cell/mm3 at ART initiation. *Other cancers include lung, liver, prostate, breast, 
melanoma, colorectal, kidney, bladder, brain, esophagus, larynx, leukemia, multiple myeloma, ovary, pancreas, peritoneum, small intestine, soft 
tissue, stomach, testicular, uterus, or non-squamous cell oral cavity/pharynx 
4
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Figure IV.4 Cancer incidence across time following initiation of combination antiretroviral therapy (ART) stratified by antiretroviral 
history at ART initiation, CFAR Network of Integrated Clinical Systems, 1996-2011.  
Graphs divided by cancer type: (A) Kaposi sarcoma, (B) Lymphoma, (C) HPV-related cancer, (D) Other cancers. Dotted lines with 
diamonds=incidence rates among those who were antiretroviral naïve at ART initiation. Dashed lines with squares=incidence rates among those 
with prior exposure to mono or dual-therapy or an unknown antiretroviral history at ART initiation. *Other cancers include lung, liver, prostate, 
breast, melanoma, colorectal, kidney, bladder, brain, esophagus, larynx, leukemia, multiple myeloma, ovary, pancreas, peritoneum, small 
intestine, soft tissue, stomach, testicular, uterus, or non-squamous cell oral cavity/pharynx
4
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V. RESULTS:  RELATIONSHIP OF IMMUNOLOGIC RESPONSE TO 
ANTIRETROVIRAL THERAPY WITH NON-AIDS-DEFINING CANCER INCIDENCE, 
CFAR NETWORK OF INTEGRATED CLINICAL SYSTEMS 
 
A. Introduction 
 
Among HIV-infected individuals the burden of non-AIDS-defining cancers (NADCs) is 
increasing[6], with malignancies such as lung cancer, anal cancer, and Hodgkin lymphoma 
contributing to substantial morbidity and mortality[6, 7, 59].  This is largely due to the aging 
of the HIV population[60, 93] as well as a higher prevalence of behavioral cancer risk factors 
such as tobacco use, alcohol use, and sexual behaviors[24].  However, HIV infection and 
the resultant immune suppression may also increase cancer risk[17, 94].  More severe 
immunosuppression, as quantified through measures such as nadir CD4 and current CD4, 
is associated with greater incidence of several NADCs[17, 35, 52, 53].  We would expect 
effective antiretroviral therapy (ART) to reduce NADC risk, but prior studies have not found 
consistent associations between ART use and lower NADC incidence[3, 62, 63, 93].  These 
inconsistencies may partly be due to differences in the effectiveness of ART between 
patients.  Immunologic response to ART is likely a major mediator of ART effects on NADC 
incidence. 
While patterns of cancer incidence differ over time after ART initiation[50, 95], the 
reasons for these patterns are not well understood, including the impact of immunologic 
ART response.  We hypothesized that a robust and prolonged immunologic response to 
ART would correlate with lower NADC incidence, and that this association would be more 
apparent after a lag time of 6-12 months.  We evaluated this hypothesis among HIV-infected 
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patients initiating a first ART regimen in the Centers for AIDS Research Network of 
Integrated Clinical Systems (CNICS) between 1996 and 2011. 
 
B. Methods  
 
Study Population 
 CNICS is a network of eight clinical U.S. HIV cohorts that collects data from HIV-
infected patients 18 years of age or older through electronic medical records[72].  CNICS 
includes detailed information from 1995 to the present on antiretroviral treatment, laboratory 
measures, demographics, and diagnoses, including cancer diagnoses which have been 
ascertained and verified through a standardized data collection process[23].  Each CNICS 
site obtained local institutional review board approval and the current study was approved 
by the University of North Carolina institutional review board. 
We included patients who initiated a first combination ART regimen, defined as ≥3 
different antiretrovirals, at one of the eight CNICS sites between Jan. 1, 1996 and Aug. 30, 
2011.  Among these patients, we included those who:  1) had a CD4 count and HIV RNA 
measure within 12 months prior to ART initiation; 2) were alive for more than six months 
after ART initiation; and 3) had at least one CD4 count and one HIV RNA measure within 
the first six months after ART initiation.   
 
Measures of Immunologic ART Response 
 Several different measures were used to characterize immunologic ART response 
based on CD4 cell count values obtained as a part of routine clinical care.  Six-month CD4 
count was used as a time-fixed measure of early immunologic response and was defined as 
the latest CD4 measurement taken within the first six months after ART initiation.  Latest 
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CD4 count was used as a time-varying measure of immunologic response and was updated 
whenever a patient had a new CD4 count result.  Finally, CD4 count-years was used as a 
time-varying measure of cumulative immunologic response.  CD4 count-years takes into 
account both the magnitude and duration of immunologic response using the trapezoidal 
rule to estimate the area under the curve across multiple CD4 count measurements.  
Specifically, the accumulation of CD4 count-years is calculated by multiplying the average of 
two consecutive CD4 counts by the time interval between the two counts and then summing 
the values across all intervals between CD4 counts.  Similar methods have previously been 
used to calculate cumulative HIV viremia[75, 76].  As an example, a patient with a CD4 
count of 300 for the entire first year after ART initiation, and a patient with a CD4 count of 
200 for the first six months and a CD4 count of 400 for the second six months, would both 
have accumulated 300 CD4 count-years one year after ART initiation. 
All immunologic measures were considered continuously and categorically to identify 
the most accurate parameterization with relation to NADC incidence. Because immunologic 
measures proximal to cancer diagnoses may be more likely to be affected by subclinical 
cancer, analyses were also done with 6-month (and 12-month) exposure lags in which 
immunologic measures were used to predict NADC diagnoses that occurred more than 6 
(and 12) months after the measurement of immunologic ART response.   
 
Statistical Analysis 
 Patient characteristics at ART initiation and patterns of immunologic response 
following ART initiation were described.  At-risk time for NADC incidence started at six 
months post-ART initiation to avoid the inclusion of cancers that developed before ART 
initiation and to allow time for at least one CD4 count to be obtained after ART initiation.  For 
analyses with 6-month and 12-month exposure lags, at-risk time started at 12 and 18 
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months, respectively, to still allow a minimum of six months to assess immunologic 
measures.  Patients remained in follow-up irrespective of ART changes or interruptions and 
were censored at the first of: death, loss-to-follow-up (>12 months without a clinic visit), last 
date of cancer ascertainment for CNICS site (range: May 31, 2010 until Aug. 31, 2011), and 
administrative censoring 10 years after ART initiation, when <15% of the study population 
was still in follow-up.   
Cox proportional hazards regression was used to estimate hazard ratios and 95% 
confidence intervals as measures of the association of immunologic response with NADC 
incidence.  Associations were considered with all NADCs, NADCs known to be related to 
viral co-infections (HPV, EBV, HBV, and HCV) (anal, Hodgkin lymphoma, liver, squamous 
cell oral cavity/pharynx, penis, and vagina/vulva cancers)[14, 23], and virus-unrelated 
NADCs.  To evaluate the proportional hazards assumption, product terms with log(time) 
were assessed.  Multivariable Cox regression was used to adjust for time-fixed confounders 
measured at ART initiation, including CD4 count, age, prior antiretroviral use, calendar year, 
race, sex, transmission risks, and CNICS site.   
Inverse-probability weights were applied to account for time-varying confounding that 
may be introduced by the close correlation of immunologic response with virologic response, 
as measured through HIV RNA measurements from the two clinical visits prior to CD4 count 
measurement[80, 82, 83].  In addition, inverse-probability-of-censoring weights were applied 
to account for differential censoring by prior HIV RNA measurements, and inverse-frequency 
weights were applied to account for differences in the frequency of obtaining CD4 count 
tests that might potentially bias exposure assessment.  For each observation, all calculated 
weights were multiplied together to create a single weight that was used in the regression 
models.   The mean total weight was 1.02 (SD=0.79).   
All immunologic measures were assessed separately as predictors in bivariable and 
weighted, multivariable regression models that accounted for both time-fixed and time-
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varying confounding.  Associations were also estimated among patients with a CD4 count at 
ART initiation <200 cells/mm3 and with a CD4 count at ART initiation ≥200 cells/mm3 to 
assess effect measure modification.  To determine which immunologic measure was the 
strongest independent predictor, AICs were calculated for each multivariable regression 
model and compared to assess the relative model fit.    
Sensitivity analyses were conducted among patients without NADC diagnoses prior 
to six months of ART and among patients who were antiretroviral naïve at ART initiation.  All 
statistical analyses were conducted using SAS version 9.2. 
 
C. Results 
 
Patient Characteristics 
 Of the 25,337 patients enrolled in CNICS at the time of this study, 11,485 initiated a 
first combination ART regimen at a CNICS site between 1996 and 2011 and had CD4 count 
and HIV RNA measures at ART initiation.  Among these 11,485 patients, 9,389 were alive 
and had obtained ≥1 HIV RNA level and CD4 count at six months after ART initiation.   
Of the 9,389 patients included, 20% were female, 43% white, and 41% black (Table 
V.1). The median age at ART initiation was 38 years (IQR: 32-45), and the median calendar 
year of ART initiation was 2004 (IQR: 2000-2007).  Most patients initiated a PI-based (47%) 
or NNRTI-based (43%) ART regimen, while a minority initiated either a regimen with both a 
PI and a NNRTI (4%), a triple-NRTI regimen (5%), or a regimen including an entry or 
integrase inhibitor (2%).  At first combination ART initiation, 27% of patients had evidence of 
prior ART exposure, including single or dual antiretroviral therapy use.  The median HIV 
RNA level at ART initiation was 4.8 log10 copies/ml and by six months post-ART initiation 
64% of patients were virologically suppressed (<400 copies/ml).   
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After six months post-ART initiation, patients were followed for a median of 3.3 years 
(IQR: 1.5-6.5) with a total of 41,538 person-years of follow-up.  Over the course of follow-up 
685 deaths occurred, and 2,339 patients were lost-to-follow-up.  Follow-up was censored for 
54% of patients at the last date of cancer ascertainment.  By 10 years after ART initiation, 
1,117 patients were still in follow-up.   
 
Immunologic response 
The median CD4 count at ART initiation was 200 cells/mm3 (IQR: 60-332).  After 
ART initiation, patients contributed a median of 9 CD4 count measurements (IQR: 4-17).  
The median CD4 count was 260 cells/mm3 (IQR: 121-419) during the first six months after 
ART initiation, 324 cells/mm3 (IQR: 182-504) during the second six months and 358 
cells/mm3 (IQR: 213-539) during months 12-18 after ART initiation.  From two years post-
ART initiation and afterward, the distribution of latest CD4 count values was stable.  Figure 
V.1 demonstrates this over the first five years of ART.  Patients accumulated a median of 
1925 cells*years/mm3 (IQR: 1239-2686) by the 54-60 month time interval after ART initiation 
equivalent to having an average CD4 count of 385 cells/mm3 over five years (Figure V.1).  
By ten years after ART initiation, the median CD4 count-years accumulated was 4572 
cells*years/mm3 (IQR: 3144-6152) equivalent to having an average CD4 count of 457 
cells/mm3 per year over ten years. 
 
Immunologic response and NADC incidence 
In total, 164 NADCs were diagnosed at a median of 3.8 years after ART initiation 
(IQR: 2.0-6.8).  Sixty-five NADCs were categorized as virus-related with the most frequent 
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being anal cancer (N=26).  Ninety-nine NADCs were virus-unrelated with the most frequent 
being lung cancer (N=22) (Table V.2). 
 In bivariable analyses, six-month CD4 count, latest CD4 count, and CD4 count-years 
were all associated with NADC incidence (Table V.3).  When examined by type of NADC, all 
immunologic measures were strongly associated with virus-related NADCs.  In weighted 
multivariable regression a 100 cell/mm3 increase in a patient’s six-month CD4 count was 
associated with a 29% lower hazard of virus-related NADC incidence (95%CI: 5%-47%) 
(Table V.3).  Similarly, a 100 cell/mm3 increase in the latest CD4 count was associated with 
a 30% lower hazard of virus-related NADC incidence (95%CI: 11%-45%).  Finally, a 200 
cells*years/mm3 increase in CD4 count-years was associated with an 8% lower hazard of 
virus-related NADC incidence (95%CI: 1%-15%).  The CD4 count-years association with 
virus-related NADC incidence was stronger among patients with a CD4 count at ART 
initiation <200 cells/mm3 (Adjusted HR: 0.89, 95%CI: 0.82-0.98) compared to patients with a 
CD4 count at ART initiation ≥200 cells/mm3 (Adjusted HR: 0.94, 95%CI: 0.81-1.08).   
Associations with other measures were not strongly modified by CD4 count at ART initiation.  
No immunologic measures were associated with virus-unrelated cancer incidence in 
bivariable or weighted multivariable analysis, even though precision was better in this group 
with a larger number of cancer events (Table V.3). 
All measures were assessed with 6-month and 12-month exposure lags.  Latest CD4 
count was less strongly associated with virus-related NADCs that occurred more than six 
months after the CD4 count measurement (Adjusted HR with 6-month exposure lag:  0.82, 
95%CI: 0.73, 0.93; Table V.3).  CD4 count-year associations with virus-related NADCs were 
slightly stronger with increased exposure lag time (Adjusted HR with 6-month exposure lag: 
0.88; with 12-month exposure lag: 0.85; Table V.3), while six-month CD4 associations were 
similar in all analyses. Associations with virus-unrelated NADCs were not identified.   
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 When the AICs from the separate models for each of the three immunologic 
response measures were compared, the AIC was lowest for the model using latest CD4 
count both in bivariable and multivariable analyses (AICs: latest CD4=1070.6, six-month 
CD4=1075.0, CD4 count-years=1076.8), indicating that this was the strongest predictor of 
virus-related NADC incidence.  However, after 6-month and 12-month exposure lags were 
implemented AICs were lowest for the model using the six-month post-ART CD4 count (6-
month lag AICs:  latest CD4=975.8, six-month CD4=972.6, CD4 count-years=974.0), 
indicating that this measure was the strongest predictor of virus-related NADCs occurring at 
least six months after measurement. 
 When immunologic measures were categorized, associations indicated that virus-
related NADC incidence decreased further with each increasing category of improved 
immunologic response.  For example, when compared to the reference category of CD4 
count-years less than 600 cells*years/mm3, CD4 count-years between 600-1600 
cells*years/mm3 had a HR of 0.83 (95%CI: 0.41, 1.65) and CD4 count-years above 1600 
cells*years/mm3 had a HR of 0.30 (95%CI: 0.10, 0.85) for virus-related NADCs (Figure V.2).   
 Similar associations were observed in sensitivity analyses in which only the 6,876 
antiretroviral naïve patients were included, and in which 382 patients with NADC diagnoses 
prior to six month post-ART initiation were excluded.  Of the 382 patients excluded with prior 
NADC diagnoses, 10 had another cancer diagnosis after six months of ART.    
 
D. Discussion 
 
In this study, a greater immunologic ART response was associated with lower NADC 
incidence, specifically for NADCs related to viral co-infections (HPV, EBV, HBV, or HCV). 
This association was independent of CD4 count at ART initiation, age and other patient 
factors considered, and was consistently observed for measures of early, time-varying, and 
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cumulative time-varying immunologic response to ART.  Inverse associations were specific 
to virus-related NADCs, while no associations were observed for virus-unrelated NADCs.  
As we did not censor patients with ART interruptions or switches, our measures of 
immunologic response are influenced by the clinical realities of ART failure or toxicity, 
consistency of ART drug supply, and patient adherence. 
CD4 count-years were used as a novel measure to capture both the degree and 
duration of immune response.  Such a measure may be particularly relevant to virus-related 
NADCs as longer periods of immune suppression may provide greater susceptibility to 
acquisition, reactivation, or persistence of oncogenic viruses.  Importantly, the magnitude of 
the association of CD4 count-years with virus-related NADC incidence increased with 
greater exposure lags indicating that the degree of immune suppression close to the time of 
cancer presentation may be less important than overall duration, likely reflecting 
oncogenesis which may occur over many years through accumulative precancerous 
intermediate steps.  While these associations were independent of immune status at ART 
initiation, cumulative immunologic ART response was most protective among patients with a 
CD4 count less than 200 cells/mm3 at ART initiation.  This relationship highlights the 
potential importance of effective ART for severely immunosuppressed as a cancer 
prevention strategy. 
Latest CD4 count was the strongest predictor of virus-related NADC incidence.  
Although this may reflect immunosuppression facilitating a transition from subclinical 
precancer to overt clinical cancer, greater immune suppression proximal to cancer diagnosis 
may conversely also be a result of immune dysregulation caused by sub-clinical cancer.  
This is specifically a concern for Hodgkin lymphoma, which is known to decrease T-cell 
populations in HIV-uninfected populations[47, 96-98].  While subclinical cancer may have 
effects on the latest CD4 count before diagnosis, it is less likely to impact CD4 measures 
less proximal to cancer diagnosis.  When cancer diagnoses were excluded that occurred 
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less than 6 and 12 months after measurement of immunologic response, all immunologic 
measures remained associated, but six-month CD4 count became the strongest predictor of 
virus-related NADC incidence.  The strong association of early immunologic response as 
captured by the six-month post-ART CD4 count may indicate that the initial immune 
reconstitution from the most severe immunosuppression levels is the most important 
component part of the immunologic ART response for reducing risk of virus-related NADCs.  
While we only explored exposure lags up to 12 months, it is also possible that associations 
would be stronger with longer exposure lags. 
 Several prior studies have found similar associations with cancer incidence.  Our 
results parallel those previously found in the ATHENA cohort, in which cumulative exposure 
to CD4 counts below 200 cells/mm3 and latest CD4 count were both associated with viral 
coinfection-related NADC risk[69].  Latest CD4 count has been shown to be associated with 
virus-related cancer incidence in a number of studies including both ART-treated and ART-
naïve populations, and these associations have been attributed to the increased risk of 
oncogenic infection[17, 53, 99].  However, as our results suggest, separating adverse 
immunologic effects of subclinical malignancy from effects of CD4 lymphopenia resulting 
solely from HIV may be difficult.   
 The interaction between inadequate immune recovery and HPV-associated 
dysplasia and malignancy may be of particular interest. Low CD4 has been found to 
increase the risk of developing cervical cytologic abnormalities[43, 46].  However, effective 
ART has not been convincingly associated with decreased risk of cervical[100] or anal 
dysplasia[101].  Multiple confounding factors including competing risks (i.e. prolonged 
survival for those on ART which may allow greater opportunities for the development of 
dysplasia and cancer) and cumulative immunologic experience may need to be accounted 
for when examining this question. Further work should be conducted examining the 
relationships between immunologic measures, specific oncogenic viruses, and 
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precancerous abnormalities, including the impact of cumulative immunologic history as 
considered in our study. 
 Given the large multi-site clinical cohort from which our results were drawn, these 
findings should be largely generalizable to U.S. HIV patients.   In addition, the use of 
comprehensive clinical data on CD4 count and HIV RNA measurements with recently 
verified cancer diagnosis[23, 102], and advanced analytic methods allowed us to accurately 
estimate cumulative and time-updated immunologic measures and adequately account for 
possible confounding due to the close correlation with virologic measures. This study is the 
first to our knowledge to estimate associations of cumulative immunologic response with 
NADC incidence and compare them to other immunologic measures in a U.S. HIV-infected 
population.   
 A number of limitations of our study should be considered.  With the exception of 
hepatitis, we could not confirm the presence of oncogenic viral infection at the time of virus-
related NADC diagnosis, and for some cancers in this category, tumors in individual patients 
may not be associated with oncogenic viruses (ex. oral pharyngeal squamous cell 
carcinoma associations with HPV).  If a poorer immunologic response increases the risk of 
viral oncogenesis, then associations found here would likely be stronger for confirmed virus-
associated cancers.  We also had limited information on behavioral risk factors for cancer, 
such as tobacco and alcohol use.  However, a previous sub-study within CNICS did not 
demonstrate associations of patient-reported tobacco and alcohol use with ART adherence, 
and thus these are unlikely to confound associations of immunologic response measures 
with NADC incidence[103].  Information was only available while patients attended a CNICS 
site.  We could not fully capture a patient’s immunologic experience prior to ART initiation, 
though we did adjust for CD4 count at ART initiation.  Additionally, one-fourth of patients 
were lost-to-follow-up and may have experienced different patterns of cancer incidence than 
those observed.  
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In sum, our findings demonstrate that multiple components of the immune response 
after ART initiation may influence risk for virus-related NADCs.  In our study, associations 
persisted after adjusting for CD4 at ART initiation, indicating that, beyond the effects of 
immune status at ART initiation, changes in immune status after ART initiation may impact 
virus-related NADC risk but not that of hitherto non-virus associated NDACs.  This highlights 
the importance of adherence to effective, durable ART which has the demonstrated benefit 
of reducing cancer risk for infection associated cancers in a population which is at increased 
risk to experience repeated episodes of infection with oncogenic viruses.   
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Table V.1 Demographic and clinical characteristics of 9389 patients with six months of 
follow-up after initiating combination antiretroviral therapy in the CFAR Network of Integrated 
Clinical Systems, 1996-2011 
Characteristic N (%) 
Total 9389 
Female Sex 1900 (20.2) 
Age† 38 (32-45) 
Race  
     White 4032 (43.2) 
     Black 3814 (40.9) 
     Hispanic 1065 (11.4) 
     Other/Unknown 478 (5.1) 
Injection drug user 1688 (18.0) 
Men who have sex with men 5192 (55.3) 
Antiretroviral exposure prior to first ART 2513 (26.8) 
ART initiation year† 2004 (2000-2007) 
ART regimen type  
     PI 4415 (47.0) 
     NNRTI 4025 (42.9) 
     3+ NRTI 458 (4.9) 
     NNRTI+PI 351 (3.7) 
     Other‡ 140 (1.5) 
HIV RNA at ART initiation (log10copies/mL)† 4.8 (4.3-5.4) 
HIV RNA <400 copies/mL at 6 months post-ART 6016 (64.1) 
CD4 count at ART initiation (cells/mm3) † 200 (60-332) 
CD4 count at 6 months post-ART (cells/mm3)† 303 (160-466) 
†Median (IQR) given instead of N (%) 
‡includes regimens with an integrase inhibitor, fusion inhibitor, or entry inhibitor 
ART=combination antiretroviral therapy, PI=protease inhibitor, NNRTI=non-nucleoside reverse 
transcriptase inhibitor, NRTI=nucleoside reverse transcriptase inhibitor 
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Table V.2 Non-AIDS-defining cancer diagnoses occurring more than six months after 
combination antiretroviral therapy initiation in the Center for AIDS Research Network of 
Integrated Clinical Systems, 1996-2011 
Type of non-AIDS-defining 
cancer 
Number of 
diagnoses 
Median time from ART initiation 
to cancer diagnosis in years 
(interquartile range) 
Total 164 3.8 (2.0-6.8) 
Virus-related 65 3.2 (1.9-5.8) 
    Squamous cell anal 25 3.8 (2.2-6.3) 
    Hodgkin lymphoma 16 2.6 (1.9-3.9) 
    Liver 13 3.7 (1.6-7.2) 
    Squamous cell oral 
cavity/pharynx 8 3.3 (1.3-6.3) 
    Other† 3 4.0 (2.5-7.7) 
Virus-unrelated 99 3.6 (1.4-6.7) 
    Lung 21 3.6 (1.0-7.0) 
    Prostate 17 4.3 (0.8-6.0) 
    Breast 10 5.2 (3.5-6.5) 
    Melanoma 9 1.9 (1.4-4.0) 
    Colorectal 7 2.7 (2.1-6.3) 
    Other‡ 35 3.0 (1.7-6.7) 
†Other virus-related cancers include penis, vaginal, and vulva.   
‡Other virus-unrelated cancers include bladder, esophagus, kidney, larynx, leukemia, multiple 
myeloma, ovary, pancreas, peritoneum, small intestine, soft tissue, testicular, thyroid uterus, or non-
squamous cell oral cavity/pharynx 
As follow-up started at 6 months after ART initiation, all included cancer diagnoses occurred at least 
0.5 years after ART initiation. 
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Table V.3  Associations of measures of immunologic response to antiretroviral therapy with non-AIDS-defining cancer incidence 
Measures of immunologic ART 
response 
Bivariable Weighted, Multivariable† 
No lag No lag 6-month lag 12-month lag 
Hazard Ratio (95% CI) 
   All NADCs                                       (N=164) (N=140) (N=125) 
Six month CD4  
(per 100 cells/mm3) 
0.90 (0.83, 0.97) 0.83 (0.72, 0.96) 0.85 (0.73, 0.98) 0.82 (0.70, 0.97) 
Latest CD4  
(per 100 cells/mm3) 
0.87 (0.81, 0.93) 0.92 (0.77, 1.09) 0.88 (0.81, 0.96) 0.91 (0.84, 1.00) 
CD4 count-years  
(per 200 cells*years/mm3) 
0.97 (0.94, 1.00) 0.98 (0.95, 1.02) 0.97 (0.93, 1.01) 0.95 (0.90, 1.01) 
Virus-related NADCs‡                       (N=65) (N=59) (N=52) 
Six month CD4  
(per 100 cells/mm3) 
0.75 (0.65, 0.87) 0.71 (0.53, 0.95) 0.69 (0.51, 0.93) 0.69 (0.50, 0.96) 
 
Latest CD4  
(per 100 cells/mm3) 
0.78 (0.70, 0.87) 0.70 (0.55, 0.89) 0.82 (0.73, 0.93) 0.81 (0.71, 0.93) 
 
CD4 count-years  
(per 200 cells*years/mm3) 
0.89 (0.84, 0.95) 0.92 (0.85, 0.99) 0.88 (0.80, 0.98) 0.85 (0.75, 0.97) 
Virus-unrelated NADCs*                  (N=99) (N=81) (N=73) 
Six month CD4  
(per 100 cells/mm3) 
0.98 (0.89, 1.07) 0.90 (0.77, 1.04) 0.94 (0.81, 1.09) 0.91 (0.77, 1.06) 
Latest CD4  
(per 100 cells/mm3) 
0.93 (0.85, 1.00) 1.01 (0.89, 1.14) 0.93 (0.84, 1.03) 0.99 (0.88, 1.11) 
CD4 count-years  
(per 200 cells*years/mm3) 
1.01 (0.97, 1.04) 1.01 (0.97, 1.05) 1.00 (0.96, 1.04) 0.98 (0.93, 1.04) 
Each association with an immunologic ART response measure was estimated using a separate regression model. 
†Total weights were applied to account for confounding from HIV RNA measurements from the prior two visits, differential censoring by prior 
HIV RNA measurements, and differential frequency of CD4 count measurements.  Multivariable analyses additionally adjusted for CD4 at ART 
initiation, HIV RNA at ART initiation, prior antiretroviral use, age at ART initiation, year of ART initiation, sex/MSM, IDU, race, CNICS study site. 
‡Virus-related NADCs included squamous cell anal, Hodgkin lymphoma, liver, squamous cell oral cavity/pharynx, penis, vagina, and vulva 
cancer. 
*Virus-unrelated NADCs included lung, prostate, breast, colorectal, melanoma, kidney, bladder, esophagus, kidney, larynx, leukemia, multiple 
myeloma, ovary, pancreas, peritoneum, small intestine, soft tissue, testicular, thyroid uterus, or non-squamous cell oral cavity/pharynx 
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Figure V.1 Distribution of latest CD4 counts and CD4 count
therapy (ART) initiation. 
Symbol=median value, Lines=interquartile range.
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-years by six month time intervals following combination antiretroviral 
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Figure V.2  Time to first virus-related NADC diagnosis by CD4 count-years category. 
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VI. DISCUSSION 
 
A. Summary of Findings 
 
 In this multi-site U.S. observational clinical cohort of 11,485 HIV-infected patients 
followed up to 10 years a total of 457 cancer diagnoses were observed, 216 of which were 
non-AIDS-defining. Distinct patterns of cancer incidence following ART initiation were 
observed for different cancer types. This likely reflects the varying etiologic contributions of 
aging, immunosuppression, and prior antiretroviral exposure, to the occurrence of specific 
cancer types, as evidenced by associations of cancer incidence with patient characteristics 
at ART initiation.  Specifically, KS incidence was strongly associated with CD4 count and 
HIV RNA at ART initiation, lymphoma incidence was associated with CD4 count and age at 
ART initiation, HPV-related cancer incidence was associated with CD4 count, age, and prior 
antiretroviral exposure at ART initiation, and other cancers were only associated with age at 
ART initiation.  Incidence did not appear to change over calendar time for any cancer type 
among ART initiators suggesting that the incremental improvements in ART regimens during 
the modern ART era have not had dramatic effects on cancer incidence. 
 Among the 9389 patients in follow-up six months after ART initiation with at least one 
CD4 count and HIV RNA measurement by that time, a positive immunologic ART response 
was found to be associated with lower NADC incidence, specifically virus-related NADC 
incidence. This protective association was independent of CD4 count at ART initiation and 
was consistently found when assessing measures of short-term immunologic ART response, 
time-varying response, and cumulative time-varying response.  However, all protective 
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associations were specific to virus-related NADCs, while no associations were found with 
virus-unrelated NADCs.  Among the different immunologic response measures, latest CD4 
count was most strongly predictive of virus-related NADC incidence and may be an 
important indicator for targeting cancer screening.  However, immune status close to cancer 
diagnosis may be affected by subclinical cancer, and thus this may be a case of reverse 
causation.  After 6-month and 12-month exposure lags were implemented, the association 
between latest CD4 count and virus-related NADC incidence was attenuated and CD4 count 
at six months post-ART initiation became the strongest predictor of virus-related NADC 
incidence.  Thus a robust early immunologic response may be of particular importance for 
preventing subsequent virus-related NADCs. 
 
B. Public Health Implications 
 
 Elucidating the relationship of antiretroviral use with the incidence of NADCs is 
clinically important for a number of reasons.  The finding that initiation of ART at higher 
CD4 counts is associated with lower cancer incidence, particularly Kaposi sarcoma, 
lymphomas, and HPV-related cancers reinforces the benefits of early initiation of ART as 
has been indicated by previous studies[104, 105].  This also highlights the importance of 
HIV testing and linkage into care as important steps in ensuring opportunities for early ART 
initiation. Understanding the effects of antiretroviral treatment response on malignancies 
can also help in targeting at-risk groups that may benefit from more frequent screening or 
prevention interventions.  Our study indicated that vigilance for Kaposi sarcoma and 
lymphoma is most important within the first year after ART initiation, and that screening 
interventions for other cancers may be best targeted after the first year on ART when 
patients are established on stable ART.  We further identified that patients with a poor 
immunologic response to ART are at higher risk for virus-related NADC incidence, and 
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thus these patients may benefit the most from prevention interventions and increased 
screening for those virus-related NADCs for which effective screening tests currently exist 
(ex. anal pap smear for early detection of anal cancer[106, 107]).   
 Finally, a better understanding of the relationship between antiretroviral treatment 
response and cancer incidence may help elucidate the etiologic pathways that increase the 
risk of cancer among HIV patients.  For instance, if better immunologic response reduces 
cancer incidence, but only after a certain lag time this may indicate that immunodeficiency 
during early HIV-infection may play an important role in the early stages of cancer even if 
later immune reconstitution is achieved.  Our results showed reduced virus-related NADC 
incidence with a better immunologic response regardless of lag time, though the strength 
of associations differed.  A poor immunologic response close to cancer diagnosis may be a 
result of subclinical cancer, but these associations may also be an indicator that immune 
suppression affects multiple steps in the oncogenic process to varying degrees. 
Understanding the interaction between the immune system and cancer risk may provide 
insights about cancer etiology that will also be applicable to the general population.  For all 
of these reasons, examining the relationship between antiretroviral use and cancer helps 
to further both the HIV and cancer research fields. 
 
C. Strengths 
 
 Our study improves upon previous studies of the relationship of ART use with 
cancer incidence because of a number of strengths.  Firstly, we used a large collaboration 
of eight different HIV observational clinical cohorts from different regions of the United 
States.  As these cohorts collect data through patient medical records, patients have little 
burden associated with study participation and the cohorts are less vulnerable to volunteer 
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and non-response bias[72, 108].  Together these characteristics make our findings broadly 
generalizable to the United States HIV clinical population. 
 Secondly, CNICS contains detailed information describing antiretroviral use, 
antiretroviral response, and other relevant variables.  Previous studies were often limited in 
that they only had information available on antiretroviral use at the time of cancer 
diagnosis, or were only able to place patients into pre-ART or ART eras based on cancer 
diagnosis dates.  The CNICS database is novel in that it contains information on individual 
antiretroviral history including precise dates of first antiretroviral exposure and dates of first 
ART regimen as well as information on the types of antiretrovirals contained in each 
regimen.  Laboratory values of HIV viral load and CD4 counts are available whenever 
taken clinically which allows for estimates of HIV disease progression and immunologic 
function both prior to and during antiretroviral treatment.  As a result, we were able to 
measure our exposure of interest in a number of ways including novel cumulative 
measures, such as CD4 count-years.  Comparisons between the different measures of 
immunologic response allow us to better identify the aspects of the immunologic response 
that are most important for NADC risk.   
 Lastly, the use of a number of advanced analytic approaches improved upon work 
previously done to assess these associations. We used inverse probability weights to 
disentangle the effects of virologic and immunologic ART response, account for differential 
censoring, and account for differential frequency of laboratory testing.  This method has 
not been commonly used in prior literature examining relationships between ART, immune 
status, and cancer risk.  This potentially resulted in residual confounding in previous 
studies.  We also incorporated exposure lags to account for the etiologic induction period 
between the effect of treatment response and cancer diagnosis.  This method likely better 
captures causal associations between immunologic response and cancer incidence than 
estimates obtained with no exposure lag. These approaches combined with a rich data 
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resource enhance the quality of the inferences that can be made from the results of this 
study.   
 
D. Limitations 
 
 While this research plan will provide new information about the relationship between 
ART, ART response, and cancer incidence through the use of a comprehensive data source 
and novel analytic methods, a number of limitations remain.  First, substance use 
information is not fully captured in the CNICS data as it is often unreliably collected in 
medical records. In addition, the data that is collected on substance use does not include 
information on the intensity of use.  As a result, these variables were not included in any of 
our analyses.  Information on sexual risk behaviors is also not regularly collected beyond the 
identification of ‘Heterosexual Sex’ or ‘Men who have sex with men’ as possible 
transmission risk factors.  While risk factors such as sexual behaviors and substance use 
may be strongly associated with risk for specific cancers, they have not been found to be 
associated with virologic and immunologic ART response[103].  However, the potential 
influence of residual confounding due to these factors must be acknowledged.  A subset of 
individuals within the CNICS cohort have consented to complete full assessments of patient-
reported outcomes including questions about transmission risk behaviors and tobacco, 
alcohol, and drug use.  In the future, this subset could be used to inform the validity of 
measures regularly collected for the larger cohort and evaluate the appropriateness of 
relying on these measures for analyses in the full cohort.   
Another potential weakness of this study population is that information can only be 
collected on patients for as long as they are attending one of the CNICS study clinics.  As a 
result, limited information is available prior to the initiation of HIV care and baseline values 
for HIV RNA and CD4 cell count are our best measures of HIV progression prior to ART 
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initiation. Moving to a different geographic area or deciding to receive HIV care from another 
facility results in loss-to-follow-up.  In addition, because information is collected through 
medical visits, the frequency of data collected for each participant is dependent upon their 
frequency of medical appointments and visit attendance.  Previous studies of visit 
attendance and retention into care at the University of North Carolina site, demonstrated 
that retention and visit attendance may be influenced by such factors as age, AIDS 
diagnosis, and proximity to the clinic[73, 109]. However, the majority of patients continue to 
receive care at the clinic for a number of years.   Overall, the 6-year probability of retention 
was 67% (95% CI: 65, 70%), similar to other HIV longitudinal studies[73].  As previously 
mentioned, inverse probability of censoring weights were applied to account for differential 
loss-to-follow-up, and inverse probability of frequency weights were applied to account for 
differences in the frequency of collection of CD4 count measurements. 
Our study also did not account for adherence or discontinuations of ART after 
initiation.  As such, exposures such as immunologic response may be driven both by the 
efficacy of the ART regimen and the adherence to the regimen.  While our approach may 
correctly estimate the causal association of immunologic response measures with NADC 
incidence, the resulting estimate does not correspond to a particular intervention.  In this 
study, we assume that adherence interventions to improve immunologic response and 
advances in treatment to improve immunologic response would have equivalent effects on 
NADC incidence.  However, this consistency assumption may be violated, as different 
interventions could potentially be used to improve a patient’s immunologic ART response 
and the resultant effects on NADC incidence may not be uniform across all 
interventions[110].  Specific interventions for improving immunologic response should be 
further evaluated to assess their impact on NADC incidence. 
The final limitation of this study is the limited ability to look at specific cancer types, 
due to the small numbers of cancer cases for individual types of cancer.  We did not have 
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adequate power to detect effects for individual cancer types and thus focused on using 
larger categories of grouped cancer types as the outcomes of interest.  It must be 
acknowledged that specific cancers within cancer groups may have differing associations 
with the exposures of interest we considered. In addition, the length of the etiologic induction 
period can differ widely between cancer types.  However, cancer types were categorized in 
biologically and epidemiologically relevant ways in order to best mitigate this limitation. 
 
E. Future Directions 
 
A number of new studies may be undertaken to further expand upon our results.  In 
addition to the immunologic response associations examined here, we plan to use similar 
techniques in order to assess associations between virologic response and NADC 
incidence.  Similar to the measures used for immunologic response, we will assess six 
month viral load, most recent viral load, and viremia copy-years[75].  Preliminary results 
from these analyses can be found in Appendix C.  In this preliminary analysis viremia copy-
years are accumulated starting at ART initiation; however, in further planned sensitivity 
analyses we will limit our patient population to those who have achieved virologic 
suppression by six months after ART initiation and then measure viremia copy-years starting 
at six months after ART initiation.  Through this method, we can more specifically estimate 
the effect of increases in viral load after initial successful viral suppression.  This may more 
specifically assess the potential effects of differences in patient adherence to their ART 
regimens.  In addition, exposure lag times and categorical parameterizations of our virologic 
response measures will be considered such as was done with the analysis of immunologic 
response. 
Another future study of importance will be evaluating the trajectories of CD4 count 
and viral load measures shortly before cancer diagnosis.  This has previously been done in 
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a study looking specifically at CD4 count trajectories before diagnosis of Hodgkin 
lymphoma.  This study identified statistically significant decreasing trends in CD4 count and 
identified this as evidence of Hodgkin lymphoma having a deleterious effect on CD4 count.  
In our study, we hypothesized that this may account for the particularly strong associations 
between latest CD4 count and virus-related NADC incidence.  However, these trends have 
not been verified in our data, and prior studies have not examined the trajectories of CD4 
count or HIV viral load among other types of cancer cases.  Using the CNICS data, a case-
crossover study could be conducted to compare trajectories during the time immediately 
before cancer diagnosis (within 6 months or a year of diagnosis) to trajectories during other 
HIV-infected time periods in the same patient[111, 112].  While such an analysis could not 
confirm a causal effect of cancer on immunologic or virologic response, it could generate 
hypotheses that could be further examined in a laboratory setting. 
We have not currently evaluated the effects of differences in the contents of ART 
regimens.  Boosted-PIs have been hypothesized to lower cancer risk[113], but these 
findings should be confirmed and could be evaluated in CNICS or other cohorts with 
detailed information on antiretroviral medications.  Additionally, specific antiretrovirals have 
been hypothesized to have effects on cancer risk such as the protease inhibitors 
nelfinavir[64, 65] and ritonavir/saquinavir[66].  Other studies have not shown associations 
between cancer incidence and antiretroviral class[67, 68], but these associations could be 
evaluated in further analysis within CNICS. 
In addition to evaluating risk factors for cancer incidence, further work should identify 
clinical characteristics associated with poor outcomes among cancer cases.  Some of this 
work has previously been conducted in CNICS[23], but further studies could better evaluate 
associations between antiretroviral exposure, time-varying CD4 counts, and time-varying 
HIV RNA measures with survival and remission following a cancer diagnosis.   
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F. Conclusions 
 
This study demonstrated that different cancer types have unique patterns of 
incidence over time after ART initiation. Incidence is predicted by a number of patient 
characteristics at ART initiation as well as immunologic response to ART.  KS and 
lymphoma had high incidence in the first six months largely driven by poor immune status at 
ART initiation.  Particularly in the case of KS, burden may be reduced substantially if HIV-
infected individuals are diagnosed and connected to clinical care before they reach CD4 
counts below 200 cells/mm3.  Incidence for other cancers increased over time from ART 
initiation, indicating the importance of screening and prevention of cancer throughout clinical 
care.  Interventions for particular cancers may be targeted based on the differing 
distributions of cancer types across time after ART initiation.  For instance, screening for 
NADCs may be best targeted after a year on a stable ART regimen.   
Calendar year of ART initiation did not affect the incidence rates of any cancer, after 
accounting for differences in patient clinical and demographic characteristics over time.  This 
may indicate that improvements in ART regimens and general HIV clinical care have not 
substantially changed cancer risk.   As a result, we can expect that cancer will continue to 
be a leading cause of morbidity and mortality in the near future and that the establishment of 
guidelines for cancer prevention and screening in the HIV population will be essential. 
While general changes to clinical care may not have had a detectable impact, a 
better immunologic response to ART is strongly associated with reduced incidence of virus-
related NADCs, even after accounting for CD4 count at ART initiation.  A robust 
immunologic response likely reduces the risk of acquisition of oncogenic viruses, as well as 
potentially reducing the persistence or loss of control of latent oncogenic viruses.  
Immunologic response within the first six months after ART initiation was the strongest 
predictor of lower virus-related NADC risk after accounting for a lag in the effect of 
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immunologic response.  This initial response is likely most important because patients are 
typically recovering from the most severe immunosuppression during this time.  This also 
highlights the importance of adherence to effective ART for the prevention of virus-related 
NADCs.  This coupled with further cancer prevention measures and increased screening 
can reduce the morbidity and mortality attributable to cancer in the HIV population.
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APPENDIX A: SENSITIVITY ANALYSES FOR CHAPTER IV 
 
 For chapter IV, sub-analyses were conducted among patients who were antiretroviral 
naïve at the initiation of their first combination ART regimen.  Baseline characteristics are 
given among patients who were antiretroviral naïve and patients with prior antiretroviral 
exposure at ART initiation in Table A.1. Associations with cancer incidence among the sub-
population of antiretroviral naïve patients are given in Table A.2.  The antiretroviral naïve 
population had a higher proportion of female patients, and Hispanic patients, and patients 
initiating an NNRTI-based ART regimen.  These patients also initiated ART in later years, 
and had higher CD4 counts and HIV RNA concentrations at ART initiation. However, the 
associations between patient characteristics and cancer incidence in this subpopulation did 
not differ noticeably from the results found in the full population including antiretroviral naïve 
and antiretroviral experience patients.
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Table A.1  Demographic and clinical characteristics of 11,485 patients initiating combination antiretroviral therapy stratified by prior 
antiretroviral experience in the CFAR Network of Integrated Clinical Systems, 1996-2011 
Characteristic N (%) ARV Naive ARV experienced 
Total 11485 8278 3207 
Female Sex 2304 (20.1%) 1579 (19.1%) 725 (6.3%) 
Age† 38 (32-45) 38 (32-45) 39 (33-45) 
Race 
   
     White 4933 (43.0%) 3530 (42.6%) 1403 (43.8%) 
     Black 4677 (40.7%) 3215 (38.8%) 1462 (45.6%) 
     Hispanic 1273 (11.1%) 1040 (12.6%) 233 (7.3%) 
     Other/Unknown 602 (5.2%) 493 (6.0%) 109 (3.4%) 
Injection drug user 2156 (18.8%) 1364 (16.5%) 792 (24.7%) 
Men who have sex with men 6328 (55.1%) 4677 (56.5%) 1651 (51.5%) 
ARV exposure prior to first ART 3207 (27.9%) - - 
ART initiation year† 2004 (2000-2007) 2005 (2001-2008) 2000 (1997-2004) 
ART regimen type 
   
     PI 5443 (47.3%) 3496 (42.2%) 1947 (60.7%) 
     NNRTI 4835 (42.1%) 4053 (49.0%) 786 (24.5%) 
     3+ NRTI 570 (5.0%) 345 (4.2%) 222 (6.9%) 
     NNRTI+PI 441 (3.8%) 227 (2.7%) 214 (6.7%) 
     Other* 196 (1.7%) 157 (1.9%) 38 (1.2%) 
CD4 count (cells/mm3)† 202 (61-338) 207 (62-338) 190 (58-339) 
HIV viral RNA (log10 copies/mL)† 4.8 (4.3-5.3) 4.9 (4.4-5.4) 4.6 (4.0-5.2) 
†Median (IQR) given instead of N (%) 
*includes regimens with an integrase inhibitor, fusion inhibitor, or entry inhibitor 
ART=combination antiretroviral therapy, PI=protease inhibitor, NNRTI=non-nucleaside reverse transcriptase inhibitor, NRTI=nucleoside reverse 
transcriptase inhibitor, ARV=antiretroviral 
7
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Table A.2  Patient characteristics at ART initiation associated with cancer incidence among antiretroviral naïve patients stratified by 
cancer group, CFAR Network of Integrated Clinical Systems, 1996-2011 
 
Bivariable Multivariable* Multivariable 2* 
 
HR (95% CI) HR (95% CI) HR (95% CI) 
Kaposi Sarcoma 
Age at ART initiation (per 10 year 
increase) 
1.06 (0.87-1.30) 1.07 (0.85-1.34) 1.07 (0.85, 1.34) 
Calendar year of starting ART 1.03 (0.97-1.08) 1.01 (0.96-1.08) 1.02 (0.96, 1.08) 
CD4 count (per 100 cells/mm3) 0.64 (0.55-0.75) 0.61 (0.51-0.73) - 
Viral load (per log10 copies/ml) 1.72 (1.29-2.30) 1.23(0.90-1.70) 1.25 (0.91-1.71) 
Nadir CD4 (per 100 cells/mm3) 0.61 (0.51, 0.73)  - 0.58 (0.47, 0.70) 
Lymphomas 
Age at ART initiation (per decade) 1.36 (1.10-1.68) 1.33 (1.07-1.66) 1.33 (1.07-1.67) 
Calendar year of starting ART 1.01 (0.95-1.07) 1.01 (0.95-1.08) 1.01 (0.94-1.08) 
CD4 count (per 100 cells/mm3) 0.79 (0.68-0.91) 0.77 (0.66-0.91) - 
Viral load (per log10 copies/ml) 1.04 (0.78-1.40) 0.81 (0.59-1.11) 0.83 (0.61-1.14) 
Nadir CD4 (per 100 cells/mm3) 0.78 (0.67-0.92) - 0.77 (0.65-0.92) 
HPV-related cancers 
Age at ART initiation (per decade) 1.52 (1.01-2.28) 1.55 (1.02-2.34) 1.55 (1.03-2.35) 
Calendar year of starting ART 0.94 (0.82-1.07) 0.96 (0.84-1.11) 0.96 (0.84-1.11) 
CD4 count (per 100 cells/mm3) 0.82 (0.62-1.07) 0.91 (0.69-1.21) - 
Viral load (per log10 copies/ml) 1.97 (1.04-3.72) 1.61 (0.82-3.20) 1.64 (0.83-3.24) 
Nadir CD4 (per 100 cells/mm3) 0.82 (0.61-1.10) - 0.92 (0.67-1.25) 
Non-lymphoma, HPV-unrelated NADCs 
Age at ART initiation (per decade) 2.44 (2.03-2.93) 2.36 (1.94-2.87) 2.36 (1.94-2.87) 
Calendar year of starting ART 1.02 (0.95-1.08) 1.00 (0.93-1.07) 1.00 (0.93-1.07) 
CD4 count (per 100 cells/mm3) 0.97 (0.87-1.09) 0.99 (0.88-1.12) - 
Viral load (per log10 copies/ml) 0.96 (0.72-1.27) 0.93 (0.68-1.26) 0.91 (0.67-1.24) 
Nadir CD4 (per 100 cells/mm3) 0.95 (0.84, 1.08) - 0.97 (0.84-1.12) 
*Multivariable analyses adjusted for other covariates listed as well as CNICS study site, sex/MSM, race, and IDU.  First multivariable model 
included latest CD4 count at ART initiation, but not nadir CD4 count.  Second multivariable model included nadir CD4 count, but not latest CD4 
count at ART initiation. 
ART=combination antiretroviral therapy, HR=hazard ratio, MSM=men who have sex with men, IDU=injection drug user, HPV=human 
papillomavirus, NADC=non-AIDS-defining cancer
7
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APPENDIX B: SENSITIVITY ANALYSES FOR CHAPTER V 
 
For chapter V, sub-analyses were conducted among patients who were antiretroviral 
naïve at the initiation of their first combination ART regimen.  Associations between 
immunologic response measures and NADC incidence among the sub-population of 
antiretroviral naïve patients are given in Table B.1.  Results from combined regression 
models in this sub-population with all immunologic measures are also given in Table B.2.  
Results did not differ dramatically from those found in the full population. 
 Analyses were also conducted in the full population with 6-month and 12-month 
exposure lags.  A subset of these results was given in Chapter V, but the full results are 
described in Tables B.3-6.  The sensitivity of results to patterns of loss-to-follow-up and 
death were examined in Table B.7 by simulating different scenarios of cancer incidence for 
the unobserved person-time (time after death or loss-to-follow-up until 10 years after ART 
initiation).  Finally, the trajectories of CD4 count measures in the year prior to a Hodgkin 
lymphoma diagnosis were examined to qualitatively assess declining CD4 counts as 
possible evidence of the effects of sub-clinical cancer.  CD4 counts did appear to decline in 
the year prior to cancer diagnosis among Hodgkin lymphoma cases and the trajectories are 
illustrated in Figure B.1. 
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Table B.1  Associations of measures of immunologic response to antiretroviral therapy (ART) with non-AIDS-defining cancer 
incidence among those with no prior antiretroviral exposure 
 
Bivariable Multivariable* 
 
 Weighted Weighted, 
Adjusted 
Measures of immunologic ART response Hazard Ratio (95% CI) 
All NADCs (N=106) 
Six month CD4 (per 100 cells/mm3) 0.91 (0.83, 1.00) 0.92 (0.83, 1.02) 0.86 (0.73, 1.02) 
Most recent CD4 (per 100 cells/mm3) 0.84 (0.77, 0.91) 0.98 (0.74, 1.29) 0.89 (0.74, 1.07) 
CD4 count-years (per 200 cells*years/mm3) 0.95 (0.91, 1.00) 0.96 (0.92, 1.00) 0.95 (0.90, 1.00) 
Viral-related NADCs (N=38) 
Six month CD4 (per 100 cells/mm3) 0.73 (0.59, 0.89) 0.72 (0.60, 0.87) 0.85 (0.60, 1.21) 
Most recent CD4 (per 100 cells/mm3) 0.70 (0.60, 0.82) 0.61 (0.47, 0.80) 0.60 (0.43, 0.84) 
CD4 count-years (per 200 cells*years/mm3) 0.85 (0.77, 0.93) 0.85 (0.79, 0.91) 0.89 (0.81, 0.98) 
Viral-unrelated NADCs (N=68) 
Six month CD4 (per 100 cells/mm3) 0.99 (0.89, 1.10) 1.00 (0.90, 1.12) 0.88 (0.73, 1.06) 
Most recent CD4 (per 100 cells/mm3) 0.91 (0.83, 1.01) 1.15 (0.86, 1.53) 0.97 (0.88, 1.08) 
CD4 count-years (per 200 cells*years/mm3) 0.99 (0.95, 1.04) 1.00 (0.96, 1.04) 0.97 (0.92, 1.03) 
*Total weights were applied to account for confounding from HIV RNA measurements from the prior two visits, 
differential censoring by prior HIV RNA measurements, and differential frequency of CD4 count 
measurements.  Multivariable analyses additionally adjusted for CD4 at ART initiation, HIV RNA at ART 
initiation, age at ART initiation, year of ART initiation, sex/MSM, IDU, race, CNICS study site. 
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Table B.2  Combined model with all immunologic ART response measures with virus-related non-AIDS-defining cancer incidence 
among those with no prior antiretroviral exposure 
 
Unadjusted  Adjusted 
Measures of immunologic ART response HR (95% CI) p-value  HR (95% CI) p-value 
Six month CD4 (per 100 cells/mm3) 0.91 (0.71, 1.17) 0.4633  1.06 (0.73, 1.53) 0.7754 
Most recent CD4 (per 100 cells/mm3) 0.73 (0.58, 0.92) 0.0072  0.70 (0.55, 0.89) 0.0034 
CD4 count-years (per 200 cells*years/mm3) 1.00 (0.87, 1.14) 0.9906  1.01 (0.88, 1.16) 0.9039 
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Table B.3  Associations between measures of immunologic response to antiretroviral therapy (ART) with 6-month exposure lags and 
non-AIDS-defining cancer incidence 
 
Bivariable Multivariable* 
 
 Weighted Weighted, Adjusted 
Measures of immunologic ART response Hazard Ratio (95% CI) 
All NADCs (N=140) 
Six month CD4 (per 100 cells/mm3) 0.90 (0.82, 0.97) 0.89 (0.82, 0.97) 0.85 (0.73, 0.98) 
Most recent CD4 (per 100 cells/mm3) 0.89 (0.83, 0.96) 0.90 (0.82, 0.99) 0.88 (0.81, 0.96) 
CD4 count-years (per 200 cells*years/mm3) 0.97 (0.93, 1.00) 0.96 (0.93, 1.00) 0.97 (0.93, 1.01) 
Viral-related NADCs (N=59) 
Six month CD4 (per 100 cells/mm3) 0.75 (0.64, 0.88) 0.76 (0.66, 0.87) 0.69 (0.51, 0.93) 
Most recent CD4 (per 100 cells/mm3) 0.83 (0.74, 0.93) 0.82 (0.72, 0.94) 0.82 (0.73, 0.93) 
CD4 count-years (per 200 cells*years/mm3) 0.88 (0.82, 0.95) 0.87 (0.80, 0.96) 0.88 (0.80, 0.98) 
Viral-unrelated NADCs (N=81) 
Six month CD4 (per 100 cells/mm3) 0.98 (0.89, 1.08) 0.98 (0.88, 1.08) 0.94 (0.81, 1.09) 
Most recent CD4 (per 100 cells/mm3) 0.94 (0.86, 1.03) 0.96 (0.86, 1.07) 0.93 (0.84, 1.03) 
CD4 count-years (per 200 cells*years/mm3) 1.00 (0.96, 1.04) 1.00 (0.97, 1.03) 1.00 (0.96, 1.04) 
*Total weights were applied to account for confounding from HIV RNA measurements from the prior two visits, differential 
censoring by prior HIV RNA measurements, and differential frequency of CD4 count measurements.  Multivariable 
analyses additionally adjusted for CD4 at ART initiation, HIV RNA at ART initiation, prior antiretroviral use, age at ART 
initiation, year of ART initiation, sex/MSM, IDU, race, CNICS study site. 
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Table B.4  Combined model with all immunologic ART response measures with virus-related non-AIDS-defining cancer incidence 
with 6-month exposure lags 
 
Unadjusted  Adjusted  
Measures of immunologic ART response HR (95% CI) p-value  HR (95% CI) p-value AIC 
Six month CD4 (per 100 cells/mm3) 0.83 (0.68, 1.00) 0.0547  0.76 (0.57, 1.02) 0.0704 972.620 
Most recent CD4 (per 100 cells/mm3) 0.98 (0.82, 1.16) 0.7948  0.97 (0.81, 1.16) 0.7285 975.806 
CD4 count-years (per 200 cells*years/mm3) 0.95 (0.86, 1.06) 0.3351  0.95 (0.85, 1.05) 0.3068 973.972 
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Table B.5 Associations between measures of immunologic response to antiretroviral therapy (ART) with 12-month exposure lags and 
non-AIDS-defining cancer incidence 
 
Bivariable Multivariable* 
 
 Weighted Weighted, Adjusted 
Measures of immunologic ART response Hazard Ratio (95% CI) 
All NADCs (N=125) 
Six month CD4 (per 100 cells/mm3) 0.89 (0.82, 0.97) 0.89 (0.81, 0.98) 0.82 (0.70, 0.97) 
Most recent CD4 (per 100 cells/mm3) 0.90 (0.84, 0.97) 0.92 (0.83, 1.02) 0.91 (0.84, 1.00) 
CD4 count-years (per 200 cells*years/mm3) 0.97 (0.93, 1.00) 0.96 (0.92, 0.99) 0.95 (0.90, 1.01) 
Viral-related NADCs (N=52) 
Six month CD4 (per 100 cells/mm3) 0.76 (0.64, 0.89) 0.76 (0.65, 0.89) 0.69 (0.50, 0.96) 
Most recent CD4 (per 100 cells/mm3) 0.80 (0.71, 0.91) 0.81 (0.69, 0.95) 0.81 (0.71, 0.93) 
CD4 count-years (per 200 cells*years/mm3) 0.87 (0.80, 0.94) 0.85 (0.76, 0.95) 0.85 (0.75, 0.97) 
Viral-unrelated NADCs (N=73) 
Six month CD4 (per 100 cells/mm3) 0.97 (0.88, 1.08) 0.97 (0.87, 1.09) 0.91 (0.77, 1.06) 
Most recent CD4 (per 100 cells/mm3) 0.97 (0.88, 1.06) 1.01 (0.90, 1.14) 0.99 (0.88, 1.11) 
CD4 count-years (per 200 cells*years/mm3) 1.00 (0.96, 1.05) 0.99 (0.96, 1.02) 0.98 (0.93, 1.04) 
*Total weights were applied to account for confounding from HIV RNA measurements from the prior two visits, differential 
censoring by prior HIV RNA measurements, and differential frequency of CD4 count measurements.  Multivariable 
analyses additionally adjusted for CD4 at ART initiation, HIV RNA at ART initiation, prior antiretroviral use, age at ART 
initiation, year of ART initiation, sex/MSM, IDU, race, CNICS study site. 
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Table B.6  Combined model with all immunologic ART response measures with virus-related non-AIDS-defining cancer incidence 
with 12-month exposure lags 
 
Unadjusted  Adjusted 
Measures of immunologic ART response HR (95% CI) p-value  HR (95% CI) p-value 
Six month CD4 (per 100 cells/mm3) 0.85 (0.70, 1.04) 0.1208  0.78 (0.58, 1.06) 0.1082 
Most recent CD4 (per 100 cells/mm3) 0.92 (0.77, 1.10) 0.3751  0.91 (0.75, 1.10) 0.3192 
CD4 count-years (per 200 cells*years/mm3) 0.95 (0.84, 1.07) 0.3688  0.95 (0.84, 1.06) 0.3506 
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Table B.7  Sensitivity of HR estimates to changes in assumptions about the unobserved incidence rates of virus-related NADCs 
among patients who died or were lost-to-follow-up in the first 10 years after ART initiation 
Simulated virus-related NADC incidence rates (per 100,000 
person-years) after censoring for individuals who do not have all 
follow-up time observed because of loss-to-follow-up or death 
HR (95% CI) 
Six-month CD4<300 Six-month CD4>=300  
Actual data* 0.71 (0.53, 0.95) 
191 191 0.75 (0.62, 0.90) 
238 238 0.79 (0.66, 0.94) 
321 321 0.81 (0.69, 0.95) 
128 238 0.91 (0.77, 1.07) 
103 470 0.94 (0.81, 1.09) 
28 639 1.04 (0.91, 1.19) 
*Total virus-related NADC incidence in actual data was 184 cases per 100,000 person-years 
Sensitivity analysis conducted for the association between CD4 count at six months after ART initiation 
and subsequent virus-related NADC incidence. 
NADC=non-AIDS-defining cancers, ART=combination antiretroviral therapy, HR=hazard ratio 
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Figure B.1  Trajectory of CD4 counts among Hodgkin lymphoma cases in the year before Hodgkin lymphoma diagnosis
8
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APPENDIX C: PRELIMINARY ANALYSES TO EVALUATE THE ASSOCIATION OF 
VIROLOGIC ART RESPONSE WITH NADC INCIDENCE 
 
 The relationship of virologic ART response with NADC incidence was evaluated in 
the study population used in Chapter V.  HIV RNA at six months, undetectable viral load at 
six months, latest viral load, and viremia copy-years were all evaluated as measures of 
virologic ART response.  Changes over time in latest viral load measures and viremia copy-
years are described in Figure C.1 and Figure C.2.  Effect estimates for the association of 
each measure with total NADC incidence, virus-related NADC incidence and virus-unrelated 
NADC incidence are given in Table C.1.  No statistically significant associations were 
identified between virologic response and any type of NADC incidence. 
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Figure C.1  Distribution of latest viral loads by six month time intervals following combination 
antiretroviral therapy (ART) initiation. 
Box= interquartile range; middle line= median; diamond= mean; “whiskers” extend to 
1.5*interquartile range. 
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Figure C.2  Distribution of viremia copy-years by six month intervals following combination 
antiretroviral therapy (ART) initiation. 
Box= interquartile range; middle line= median; diamond= mean; “whiskers” extend to 
1.5*interquartile range.  
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Table C.1  Bivariable and multivariable associations of virologic ART response with non-AIDS-defining cancer incidence stratified by 
cancer group, Center for AIDS Research Network of Integrated Clinical Systems, 1996-2011 
 
 
Unadjusted Adjusted* 
Measures of virologic ART Response Hazard Ratio (95% CI) 
All NADCs (164 cases) 
HIV RNA (per log10 copies/ml) 1.07 (0.93, 1.22) 1.05 (0.90, 1.22) 
Undetectable HIV RNA (<400 copies/ml) 0.97 (0.69, 1.35) 0.95 (0.67, 1.37) 
Latest HIV RNA (per log10 copies/ml)  0.98 (0.86, 1.11) 0.99 (0.86, 1.15) 
Viremia copy-years (per log10 copies*year/ml)     1.12 (0.94, 1.33) 1.12 (0.89, 1.41) 
Viral-related NADCs (65 cases) 
HIV RNA (per log10 copies/ml) 1.07 (0.86, 1.33) 0.96 (0.76, 1.23) 
Undetectable HIV RNA (<400 copies/ml) 0.74 (0.45, 1.23) 0.94 (0.53, 1.65) 
Latest HIV RNA (per log10 copies/ml) 1.00 (0.82, 1.22) 1.04 (0.82, 1.34) 
Viremia copy-years (per log10 copies*year/ml) 1.18 (0.90, 1.55) 1.11 (0.75, 1.65) 
Viral-unrelated NADCs (99 cases) 
HIV RNA (per log10 copies/ml) 1.06 (0.88, 1.27) 1.10 (0.90, 1.33) 
Undetectable HIV RNA (<400 copies/ml) 1.18 (0.75, 1.84) 1.07 (0.66, 1.73) 
Latest HIV RNA (per log10 copies/ml) 0.96 (0.82, 1.13) 0.95 (0.81, 1.12) 
Viremia copy-years (per log10 copies*year/ml) 1.08 (0.86, 1.35) 1.13 (0.86, 1.49) 
*Multivariable analyses weighted inverse probability of observed viremia copy-years given the CD4 count measures from prior 
two visits and CD4 count at ART initiation.  Multivariable analyses additionally adjusted for prior antiretroviral, age at ART 
initiation, year of ART initiation, sex/MSM, IDU, race, CNICS study site 
ART=combination antiretroviral therapy, NADC=non-AIDS-defining cancer, CI=confidence interval 
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